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It is with great pleasure that I welcome you to the 
annual 29th Congress of the Mediterranean League 
of Angiology and Vascular Surgery to be held 
next November in Zagreb, Croatia. President of the 
Organizing Committee is Dr Ivan Cvjetko, National 
Representative of MLAVS in Croatia. 
The Mediterranean League of Angiology and Vascular 
Surgery has a multidisciplinary character, providing 
a unique forum for discussion of all critical issues 
concerning the management and care of vascular 
patients.
Furthermore, MLAVS has a mission to foster progress 
and mutual understanding between all professional 
groups dealing with vascular diseases in the 
Mediterranean region, and to promote research for a 
better understanding of genetic and environmental 
factors as well as molecular mechanisms of vascular 
diseases.
This Congress will be organised in beautiful 
environment of the City of Zagreb and will includ 
joint symoisa with Asian Society for Vascular Surgery 
and IUA youth committee. On behalf of the Executive 
Board of the Mediterranean League of Angiology and 
Vascular Surgery I would like to invite you to Croatia 
next November for a successful and productive 
Meeting. 
Let’s meet in Zagreb!
Professor Nikos S. Angelides MD, PhD, FRCS 
President of the Mediterranean League of Angiology and Vascular Surgery
LOCAL ORGANIZER WELCOME ADDRESS
Distinguished colleagues and dear friends,
It is a great honour and pleasure to extend my 
greetings to you on behalf of the Local Organizing 
Committee and invite you to participate in The 
XXIX Congress of the Mediterranean League of the 
Angiology and Vascular Surgery (MLAVS) which will 
take place from the 7th to the 9th of November 2019 
in Zagreb, Croatia.
The organizers have invited numerous international 
speakers, with the intention to present the newest 
scientific knowledge in the field of vascular surgery 
and vascular medicine. 
Lectures are designed for: vascular surgeons, 
endovascular surgeons and interventionalists, cardiac 
surgeons, cardiologist, neurologists, physicians in 
training, vascular scientists and nurses.
Along with the professional work, we will try to spend 
our time in socializing and getting to know each 
other, and Zagreb, the capital of Croatia will certainly 
allow us to do so.
With best regards and looking forward to seeing you 
in Zagreb!
Professor Miljenko Kovačević, MD, PhD 
President of CSVS
Ivan Cvjetko, MD, PhD 
Organizing Committee President CSVS 
MLAVS National Representative, Croatia 
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UNDER THE AUSPICES OF
• Ministry of Health of the Republic of Croatia





1. Open and endovascular treatment  
of thoracic aorta
2. Open and endovascular treatment  
of abdominal aorta
3. Visceral arteries
4. Carotid artery disease
5. Peripheral arterial disease
6. Critical limb ischaemia
7. Diabets and vascular disease
8. NOACS
9. Lipid lowering therapy
10. Nutrition in Vascular surgery
11. Chronic venous insu_ciency




16. Infections in vascular surgery




  2019 MLAVS participant Registration fee Registration fee Registration fee
      paid until 05/10/19 paid after 05/10/19 On-site payment
  MLAVS member*  € 300,00  € 350,00   € 400,00
  MLAVS non-member*             € 400,00  € 450,00  € 500,00
  IUA Youth member* /  
  doctor under 45 years  € 100,00  € 150,00  € 200,00
  Student**   € 100,00  € 150,00  € 150,00
  Accompanying person  € 120,00  € 130,00  € 140,00
VAT included.





Thursday, November 7, 2019
17:00 - 19:00 Registration
18:50 - 19:00 Congress opening 
  Welcome address - Prof. Nicos Angelides, president of MLAVS  
  Welcome address - Prof. Miljenko Kovačević, president of CSVS
19:00 - 19:45 Opening lecture - Nicos Angelides, Cyprus: „Historical Overview of the Mediterranean  
  League of Angiology and Vascular Surgery so far“
19:45 - 20:15 Reuven Zimlichman, Israel: History of Hypertension and the arterial system
20:15 - 20:45 Stella Fatović Ferenčić, Croatia: Đuro Armen Baglivi: from Dubrovnik  
  to international scientific community
Friday, November 8, 2019 
HALL A
09:00 - 10:30 AORTIC 
  Chairmen: Miljenko Kovačević, Christian Behrendt, Ivan Burcar, Joško Bulum, Endre Kolossavary
  Endre Kolossavary, Hungary: Vascular registry and administrative data assessments
  Christian Behrendt, Germany: Impact of weekend treatment on short-term and long-term  
  survival after urgent repair of ruptured aortic aneurysms in Germany
  Jose Fernandes e Fernandes, Portugal: Popliteal Artery Aneurysms: Challenges and Outcomes.
  Ivan Burcar, Croatia: Thoracic aorta
  Joško Bulum, Croatia: TEVAR
  Konstantin Andreychuk, Russia: Open repair of ruptured abdominal aortic  
  aneurysms: the results in elderly patients
10:30 - 11:00 PLENARY SESSION – BALAS LECTURE 
  Jose Fernandes e Fernandes, Portugal: Modern Management of Aortic Aneurysms -  
  Time for Reflection and the Education of Future Vascular Surgeons
11:00 - 11:30 Coffee break
11:30 - 13:15 AORTIC 
  Chairmen: Igor Rudež, Hubert Schelzig, Mladen Gasparini, Daniel Unić
  Igor Rudež, Croatia: Lansac technique: best of both worlds in aortic root  
  valve sparing surgery
  Hubert Schelzig, Germany: Clinical and technical considerations in patient specific aortic  
  stengraft design
  Mladen Gasparini, Slovenia: Is minilaparotomy for the treatment of AAA still an option
  Saleh Amro, Russia: Mini-laparatomic access versus laparotomy in abdominal  
  aortic disease treatment
  Daniel Unić, Croatia: Vascular access options for transcatheter aortic valve implantation
  Giselle Marie Ortiz, Panama: Aortic rupture with contained hematoma -  
  endovascular management
  Josip Figl, Croatia: Case report of an emergency common carotid to subclavian artery  




13:15 -13:45 PLENARY SESSION – SPECIAL LECTURE 
  Reuven Zimlichman, Israel: New hypertension Guidelines, the European,  
  the American and their significance
13:45 - 15:00 Lunch break   
13:30 - 15:00 MLAVS, Meeting of the Executive Committee - KORNATI ROOM
15:00 - 16:45 CAROTID Joint Symposium MLAVS / CEVF 
  Chairmen: Salvatore Novo, Karel Rotzocil, Pavel Poredoš, Jose Fernandes e Fernandes
  Pavel Poredoš, USA: Characterization of structure of carotid plaques and its  
  clinical relevance
  Salvatore Novo, Italy: Carotid preclinical atherosclerosis predicts future  
  cardiovascular events
  Hrvoje Budinčević, Croatia: The role of ultrasonography in the management  
  of carotid artery disease.
  Jose Fernansdes e Fernandes, Portugal: Carotid disease - where we stand and challenges  
  for the future. The asymptomatic carotid disease
  German Sokurenko, Russia: The influence of technique of carotid endarterectomy on  
  results in symptomatic patients
  Christos Liapis, Greece: Selected asymptomatic patients should be revascularized:  
  Medical therapy must be optimized
  Stanislav Ordynets, Russia: Determination of indications for surgical treatment with a  
  combination stenosis and tortuosity of the internal carotid artery in acute ischemic stroke
16:45 - 17:15 Coffee break
17:15 - 18:45 CHRONIC WOUNDS 
  Chairmen: Patrick. H Carpentier, Tanja Planinšek Ručigaj, Sandra Marinović Kulišić, Ana Jović
  Patrick. H Carpentier, France: Arterial evaluation in patients with leg ulcers 
  Nicos Angelides, Cyprus: No-option CLI: Novel ways of treatment
  Ana Jović, Croatia: Vascular surgeon and chronic wounds
  Tanja Planinšek Ručigaj, Slovenia: Application of compression therapy  
  in the treatment of lymphedema
  Nastja Kučišec Tepeš, Croatia: Chronic surgical wounds and biofilm
  Saleh Amro, Russia: The experience of successful use of Negative-pressure wound therapy  
  in patients with infectious complications after surgery on the aorto-iliac and  
  femoral-popliteal segments
  Tamara Sinožić, Croatia: Interdisciplinary approach to the patient with hard to heal  
  venous leg ulcer – case report
HALL B
09:00 - 10:30 VENOUS 
  Chairmen: Louay Altarazi, Karahan Oguz, Lovro Tkalčič, Thais Duailibi
  Oguz Karahan, Turkey: Sealing in varicose veins
  Lovro Tkalčič, Croatia: Inpact of endovascular management of arteriovenous  
  fistula malfunction in preserving hemodyalises access
  Oguz Karahan, Turkey: Interventional treatment of deep venous thrombosis.  




  Tankut Akay, Turkey: Surgical treatment of Tumors in big veins
  Thais Duailibi, Brazil: Endovascular treatment of thoracic central vein occlusion stent  
  (previous intervention) with a parallel stent
  Louay Altarazi, Syria: Fluoroscopy guided blocked Saphenous veins sclerotherapy,  
  another point of view
10:30 - 11:00 PLENARY SESSION – BALAS LECTURE, HALL A 
  Jose Fernandes e Fernandes, Portugal: Modern Management of Aortic Aneurysms -  
  Time for Reflection and the Education of Future Vascular Surgeons
11:00 - 11:30 Coffee break
11:30 - 13:15 PAD 
  Chairmen: Tanku Akay, Tomislav Šipić, Angmapally Rajeev, Nicola Troisi
  Tankut Akay, Turkey: Pulmonary endarterectomy for CTEPH (chronic thromboembolic  
  pulmonary hypertension)
  Sandeep Raj Pandeey, Nepal: Endovascular management of SFA disease
  Angmapally Rajeev, USA: Diabetic ischemic foot...Recognize,  
  revascularize to prevent amputation
  Tomislav Šipić, Croatia: PTA procedures after previous vascular surgery
  Leonid Magnitskiy, Russia: Superficial femoral and popliteal arteries long occlusions.  
  Another way of revascularization
  Tankut Akay, Turkey: Critical leg ischemia, the ultimate debate, open versus endovascular
  Nicola Troisi, Italy: Pedal arch in diabetic patients
13:15 - 13:45 PLENARY SESSION – SPECIAL LECTURE, HALL A 
  Reuven Zimlichman, Israel: New hypertension Guidelines, the European,  
  the American and their significance
13:45 - 15:00 Lunch break
15:00 - 16:45 ABBOTT - Satelite symposium, Nutrition 
  Ante Ivkošić, Croatia: Correlation of nutritional interventions and  
  pathophysiology of chronic wounds
  Ante Kanjer, Croatia: Specific nutritional interventions in the healing  of chronic wounds
16:45 - 17:15 Coffee break
HALL C
11:30 - 13:15 NOACS 
  Chairmen: Pavel Poredoš, Pier Luigi Antignani, Ingrid Prkačin, Matija Kozak
  Reuven Zimlichman; Israel: Cardiovascular effects of the tobacco Heating System (THS)  
  compared with continued smoking
  Pavel Poredoš, USA: Inflammation and venous thrombosis: what is the connection?
  Ingrid Prkačin, Croatia: NOACS in VTE and PAD
  Pier Luigi Antignani, Italy: Can we reduce the incidence of PTS?
  Matija Kozak, Slovenia: Thrombolytic treatment of pulmonary embolism
  Petra Pervan, Croatia: Beeding as a major cause of emergency attendance in patients on  




13:15 -13:45 PLENARY SESSION – SPECIAL LECTURE, HALL A 
  Reuven Zimlichman, Israel: New hypertension Guidelines, the European,  
  the American and their significance
13:45 - 15:00 Lunch break
15:00 - 16:45 NEWS IN PHLEBOLOGY 
  Chairmen: Louay Altarazi, Pandeey Sandeep Raj, Sorin Oliaru, Larisa M. Chernukha,  
  Christopher R Lattimer
  Sorin Oliaru, Romania: Endovascular treatment of chronic venous disease  
  (foam, laser, RF and glu)
  Francesco Zini, Italy: SFALT: new proposal for the treatment of varicose veins
  Louay Altarazi, Syria: Pelvic congestion syndrome unknown aspects
  Christopher R Lattimer, UK: Chronic venous obstruction:  
  what is it and how can we measure it?
  Sandeep Raj Pandeey, Nepal: Endovenous heat induced thrombosis
  Larisa M. Chernukha, Ukraine: Cancer related DVT: what’s news?
  Boštjan Leskovar, Slovenia: (Re)construction of arteriovenous fistula with cormatrix
16:45 - 17:15 Coffee break
17:15 - 17:45 CHRONIC VENOUS INSUFFICIENCY TREATMENT: SYNERGY OF VENOACTIVE  
  DRUGS AND SURGERY 
  Chairmen: Miljenko Kovačević, Ante Kanjer, Damir Flam, Ivan Cvjetko
  Ivan Cvjetko, Croatia: Benefits of venoactive drug therapy in surgical or  
  endovenous treatment for varicose veins
  Ante Kanjer, Croatia: Case report 1: MPFF therapy in surgical treatment 
  Damir Flam, Croatia: Case report 2: MPFF therapy in endovenous treatment 
  Dinko Lupi, Croatia: Challenges of venoactive drug producers
Saturday, November 9, 2019 
HALL A
09:15 - 09:30 PLENARY SESSION – SPECIAL LECTURE 
  Nicos Angelides, Cyprus: The use of a nine step therapeutic ladder in PAD and CLI 
09:30 - 10:45 PAD AND RADIATION PROTECTION 
  Chairmen: Nicos Angelides, Jose Fernandes e Fernandes, Tomislav Krčmar, Bahare Fazeli
  Pavel Poredoš, USA: Secondary prevention of PAD
  Jose Fernandes e Fernandes Jose, Portugal: Peripheral arterial disease in hospital  
  admissions in Portugal and the impact of endovascular technology. When is open surgery  
  still the best solution available?
  Bahare Fazeli, Iran: Angiogenesis induction in Buerger’s disease: a disease management  
  double-edged sword?
  Tomislav Krčmar, Croatia: Radial access for peripheral vascular interventions  
  and diagnostics
  Jelena Popić, Croatia: Radiation protection in vascular surgery





09:15 - 10:45 UEMS/ YOUTH session IUA /ESVST 
  Chairmen: Marko Ajduk, Steffano Ancetti, Leonid Magnitskiy, Amir Arnautović
  Vojko Flis, Slovenia: Vascular and endovascular surgery in Slovenia
  Amir Arnautović, Germany: How to become a vascular and endovascular surgeon as well  
  as endovascular specialist in Germany
  Marko Ajduk, Croatia: Vascular surgery in Croatia
  Stefano Ancetti, Italy: Improving training opportunities Europe:  
  European vascular surgeons in training (EVST)
  Leonid Magnitskiy, Russia: The European vascular Surgeons in training (EVST),  
  call for Croatia
  Kristina Tomašić, Croatia: Symptomatic AAA and chronic Stanford A Dissection
11:00  Professor ŠOŠA Award Congress Closure
12:00  Transport to Opatija (excursion for invited speakers)
POSTERS
1.  LIMB SALVAGE PROCEDURE VERSUS AMPUTATION – THE CREDIBILITY OF MANGLED EXTREMITY 
 SEVERITY SCORE (MESS) IN SEVERELY INJURED LIMBS 
 Ali Allouch, Damir Koprek, Neven Mesar, Victor Allouch, Zrinka Sudar-Magaš, Branko Fila;  
 General Hospital Bjelovar, Bjelovar, Croatia 
2.  IN SITU ABDOMINAL AORTIC RECONSTRUCTION WITH CRYOPRESERVED ALLOGRAFT IN SETTING 
 OF GRAFT INFECTION 
 Evgeniya Bulda, A Koren, G Sivak; Rabin Medical Center, Campus Beilinson, Petah Tikva, Israel
3.   OPEN SURGERY REPAIR OF RUPTURED GIANT INTERNAL ILIAC ARTERY ANEURISM: A CASE REPORT 
 Muhamed Djedovic1, A Hadzimehmedagic1, H Vranic1, D Totic1, B Imsirovic2;  
 1University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina,  
 2General Hospital “Prim.dr. Abdulah Nakas” Sarajevo, Sarajevo, Bosnia and Herzegovina
4.  LOWER LEG COMPARTMENT SYNDROME IN A PATIENT USING DABIGATRAN 
 Inga Đaković Bacalja1, Damir Koprek1, Tomislav Krejčir1, Dejan Baljak1, Mirjana Gracin2,  
 Tomislav Meštrović3;  
 1General Hospital Bjelovar, Bjelovar, Croatia, 2Special Hospital for Pulmonary Diseases,  
 Rockfellerova, Zagreb, Croatia, 3University Hospital Centre Zagreb, Zagreb, Croatia
5.  DOSE DEPENDENT DRUG-DRUG INTERACTIONS WITH DABIGATRAN 
 Juraj Jug1, Ingrid Prkačin2;  
 1School of Medicine, Zagreb, Croatia, 2Clinical Hospital Merkur, Zagreb, Croatia
6.  MODIFIED METHOD OF EVERSION CAROTID ENDARTERECTOMY IN PATIENTS WITH EXTENSIVE 
 ATHEROSCLEROTIC DISEASE OF CAROTID BIFURCATION: SHORT-TERM RESULTS 
 Vladislav Panfilov1, Anatoly Virgansky1, Konstantin Romanenko2, Konstantin Siniakin2;  
 1Pirogov Russian National Research Medical University, Department of Faculty Surgery, Moscow,  
 Russian Federation, 2Vinogradov City Hospital, Department of Vascular Surgery, Moscow, Russian   
 Federation
FINAAL PROGRAM
Acta Chirurgica Croatica Abstracts of Oral presentations
The XXIX Congress of the Mediterranean League off the Angiology  
and Vascular Surgery (MLAVS)




Acta Chirurgica CroaticaAbstracts of Oral presentations
THE HISTORY OF HYPERTENSION AND THE ARTERIAL SYSTEM
Reuven Zimlichman
Director of the Brunner institute for Cardiovascular Research, Tel Aviv University, Tel Aviv, Israel
zimlich@bezeqint.net
The interest in studying the blood vessels, the heart 
and the pressure within the blood vessels, started 
at very early stages of medical research and efforts 
of understanding the human body. These are 
mentioned by historians, about 3-4 thousands of years 
B.C. in the Egyptian papyri and in ancient Chinese 
records. During the years, additional information 
gradually accumulated, the structure and function 
of the closed circulatory cycle was understood 
and described. Then the efforts concentrated on 
development of an accurate, convenient and reliable 
device for blood pressure measurement, which will 
be used in all doctors’ in their clinics. In the beginning 
of the 19th century several convenient, portable and 
reliable devices were developed. In these times, huge 
amounts of data accumulated mainly in the hands 
of the insurance companies, which needed used 
these data for estimation of morbidity and mortality 
induced by elevated blood pressure in order to 
determine the prices of insurance policies. In the 
next years, blood pressure measurements became 
a routine in all physical examinations and became 
compulsory for issuing an insurance policy. 
At this stage, a great discrepancy was present by the 
“insurance medical world” and between the “real 
medical world”. At that stage, insurance companies 
already started to charge extra cost in those with 
mildly elevated blood pressure while the medical 
world still disputed whether elevated blood pressure 
should be treated at all. Then, severely elevated 
blood pressure levels were started to be treated but 
with very few medications which had severe side 
effects. At later stages, new medications appeared 
and the blood pressure of many hypertensive could 
be balanced with a favorable side effect profile. 
Today, after thousands of years we are still in dispute 
about the definition of normal blood pressure, goal 
blood pressure and the proper therapeutic approach 
to various subgroups of hypertensive patients.
ĐURO ARMEN BAGLIVI: FROM DUBROVNIK TO INTERNATIONAL  
SCIENTIFIC COMMUNITY
Stella Fatović Ferenčić
Head of the Department for the History of Medical Sciences,¨Croatian Academy of Sciences and Arts
Zagreb, Croatia
The physician, born in Dubrovnik of an Armenian 
family naturalized Italian, Đuro Armen Baglivi (1668 
- 1707) represents the noticeable member of 17th 
century medicine.  
After his graduation in Salerno in 1688, Italian medical 
centers of excellence such as Padua, Florence, Pisa 
and especially Bologna opened him the doors 
frequented by the best known figures in the medical 
milieu of the time. 
This presentation will illustrate his production 
ranging from the De praxi medica to the De fibra 
motrice, which played an important role in further 
development of medical science and were further 
cited in European literature well into the 19th century. 
14
Acta Chirurgica Croatica Abstracts of Oral presentations
AORTIC 
VASCULAR REGISTRY AND ADMINISTRATIVE DATA ASSESSMENTS
Endre Kolossvary, Ferenci Tamás, Kováts Tamás
St Imre University Teaching Hospital, Dept. of Angiology, Budapest, Hungary
kolossendre@gmail.com
Keywords: Big data, Vascular Registries, Healthcare 
Administrative Data Analysis
Although prospective randomized-controlled trials 
are considered as the most reliable form of scientific 
evidence, these trials often cannot be conducted 
because of ethical, financial, and practical reasons. 
They support only partially the existing treatment 
guidelines on vascular field. Research based on 
vascular registries and administrative datasets 
represents a significant change in addressing 
scientific questions on population scale. A large 
sample size typically represents a larger proportion 
of the population of interest, thereby reducing 
sampling error and increasing external validity. 
Additionally, several other virtues can be recognized 
favoring this kind of research as the possibility to 
assess rare conditions, lower-cost demand, more 
extended data capture, the inclusion of spatial data 
for analysis. However, numerous methodological 
issues may question the value of the results and 
arouse doubts regarding the interpretation of the 
analysis. In many aspects, these methodological 
problems are different compared to the traditional 
approach of epidemiological research. The 
presentation aims to summarize the characteristics 
and limitations of research on vascular registry and 
healthcare administrative data.
Raising consciousness on the virtues and 
shortcomings of the population scale assessments of 
these kinds is inevitable to leverage these promising 
resources.
AORTIC 
IMPACT OF WEEKEND TREATMENT ON SHORT-TERM AND LONG-TERM 
SURVIVAL AFTER URGENT REPAIR OF RUPTURED AORTIC ANEURYSMS IN 
GERMANY
Christian-Alexander Behrendt1, Art Sedrakyan2, Thea Schwaneberg1, Tilo Kölbel1,  




Keywords: Rupture; Aortic aneurysm; Weekend 
effect; Survival analysis; Health insurance claims
Objective: There is some evidence that weekend 
admission to the hospital is associated with worse 
outcomes compared with weekday admission. 
However, only a few studies have focused on 
weekend vs weekday surgery outcomes. This study 
aimed to determine whether there is a weekend 
effect on outcomes in the treatment of ruptured 
aortic aneurysms in Germany.
Methods: Health insurance claims of Germany’s 
third largest insurance provider, DAK-Gesundheit, 
were used to investigate short-term and long-term 
mortality after weekend vs weekday treatment of 
ruptured aortic aneurysm. Patients undergoing 
endovascular repair (ER) or open surgical repair 
(OSR) between January 2008 and December 2016 
were included in the study. Both propensity score 
matching and regression methods were used to 
adjust for confounding.
Results: Therewere 1477 patients in the cohort, of 
whom 517 (35.0 %) underwent ER and 960 (65.0 %) 
OSR. Overall, 995 (67.4 %) patients underwent an 
operation on week days (Monday to Thursday), and 
482 (32.6 %) patients underwent an operation on a 
weekend (Friday to Sunday). In multivariable models, 
AORTIC 
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patients who underwent an operation on a weekend 
were at higher risk of in-hospital death after OSR 
(49.2 % vs 38.0 %; odds ratio [OR], 1.61; P Ľ .001), 
and there was a trend toward higher in-hospital 
mortality after ER (29.5 % vs 21.2 %; OR, 1.55; P Ľ 
.056). The ER of thoracic or thoracoabdominal aortic 
ruptures was associated with significantly higher in-
hospitalmortality compared with ER of abdominal 
aortic aneurysm (OR, 1.69; P Ľ .026).
Conclusions: Weekend repairs of ruptured aortic 
aneurysms are associated with worse in-hospital 
survival compared with weekday surgery. ER of 
thoracic or thoracoabdominal aortic ruptures is 
associated with worse in-hospital survival compared 
with ER of ruptured abdominal aortic ruptures. This 
might be an international phenomenon requiring 
joint learning and action in times of centralization of 
aortic procedures. (J Vasc Surg 2019;69:792-9.)
AORTIC 
POPLITEAL ANEURYSMS - CHALLENGES AND OUTCOMES.  IS OPEN REPAIR 
STILL THE GOLD STANDARD? AND WHAT APPROACH IS BEST – MEDIAL OR 
POSTERIOR?
Jose Fernandes e Fernandes
Faculty of Medicine, University of Lisbon, Portugal
Lisbon Cardiovascular Institute / Hospital da Luz Torres de Lisboa, Lisbon, Portugal
jff@me.com
Popliteal artery aneurysms (PAA) are the most 
common peripheral aneurysms, frequently bilateral 
and in 30% to 50% associated with abdominal aortic 
aneurysms and represent if untreated a major cause 
of very severe ischemia and major amputation.
Embolization from sac thrombotic material, acute 
thrombosis and concomitant presence of occlusive 
disease are major challenges for a successful 
treatment. Indications for intervention on PAA are 
size > 2.0 cms, presence of intra-sac thrombus, 
compression of adjacent anatomic structures 
such as nerves or popliteal vein, evidence of distal 
embolization and rupture, a much rare event when 
compared with aortic aneurysms. PAA location can 
be diffuse with involvement of the entire popliteal 
artery, segmental in the middle third of the artery 
where it can be associated with extrinsic compression 
like the popliteal entrapment syndrome or can be 
part of a multi-aneurysmal disease involving other 
major arteries.
Diagnosis is based on modern imaging technologies 
like EcoDoppler, CT-Angio and angiography still 
required for a better identification of associated 
occlusions essential for the best choice of treatment.
Open repair has been the first line of treatment based 
on exclusion of the aneurysm through the medial 
approach or resection of the aneurysm through 
the posterior approach plus revascularization with 
adequate conduit, long saphenous vein being the 
best and most durable alternative.
Endovascular technology has introduced a new 
treatment strategy and became a solid alternative 
in asymptomatic aneurysms, with suitable anatomy 
and absence of distal occlusive disease.
We reviewed our experience of 97 patients, 140 
popliteal artery aneurysms (PAA) in which 79% were 
managed by an open procedure and 21% by an 
endovascular procedure and compared the early 
and late outcomes in terms of survival, primary and 
secondary patency rates, limb preservation and 
freedom from reintervention, concluding that open 
repair offers excellent results when performed with 
a suitable venous conduit. Endovascular technology 
in selected patients may offer a valid alternative 
provided there is adequate proximal and distal 
landing zones and in the absence of associated distal 
arterial occlusions. In acute thrombosis no evidence 
has yet proved the efficacy of endovascular repair 
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OPEN REPAIR OF RUPTURED ABDOMINAL AORTIC ANEURYSMS:  
THE RESULTS IN ELDERLY PATIENTS
Konstantin Andreychuk, G Sokurenko, E Kiseleva, N Andreychuk 
The Nikiforov Russian Center of Emergency Medicine, St. Petersburg, Russia
andreychuk@cvsurgery.ru
Keywords: abdominal aneurysm, elderly patients
Objective: Immediately repair is the only potentially 
life-saving procedure for patients with ruptured 
abdominal aortic aneurysms (RAAA). Otherwise, 
the advanced age is an independent and significant 
predictor of poor outcome, especially for emergency 
repair. It is thought that such major procedure, 
even successful, doesn’t increase a life time in 
elderly persons, but impairs the life quality and is 
unreasonably cost-intensive. This circumstance can 
restrict not only referral for surgery from general 
physicians, but also a decision of open repair by 
vascular surgeons in absence of capability for 
emergency EVAR. The aim of this study was the 
analysis of long-term results of open repair in elderly 
patients.
Methods: During fifteen years 103 patients aged 
76 and older underwent open repair of RAAA in our 
center. 58 of them survived 30 days after surgery 
minimally and were discharged. All of them were 
included in this analysis, 16 octogenarians and 4 
nonagenarians at the time of baseline included. The 
duration of long-term follow-up amounted to 151 
months.
Results: A median survival after the baseline as a 
main criterion was evaluated. The common median 
for all included patients amounted to 74 months. 
The longest survival life (88 months) time was for 
persons up to age 79 inclusive. The median survivals 
for octogenarians and nonagenarians were 29 and 
14 months respectively. Cardiovascular events 
were the main cause of death. In addition, the 
assessment of health-related quality of life (HRQoL) 
indicators through the use of SF-36 was performed 
for definition of social value of life time increase. The 
results of assessment demonstrated to ‘non-repaired’ 
population comparable results for Physical Health 
(PH) and exceeding results for Mental Health (MH).
Conclusion: The results of this study provide 
sufficient grounds to believe that open repair of 
RAAA can be allowable choice in selected cases even 
for elderly patients.
AORTIC 
LANSAC TECHNIQUE: BEST OF BOTH WORLDS IN AORTIC ROOT VALVE 
SPARING SURGERY
Igor Rudež
University Hospital Dubrava, Zagreb, Croatia
rudi@kbd.hr
Keywords: Aortic root surgery, Valve sparing 
procedures
Valve sparing aortic root surgery for aortic 
regurgitation is still technicaly challenging and 
demanding. Two widely accepted methods (Yacoub’ 
and Davis’s technique) have serious drawbacks in 
certain population of patients, and are not applicable 
for all. Surgical technique proposed by Emmanuel 
Lansac in step-by-step approach combines the best 
of both worlds, and seems to offer durable solution 
not only for patients with enlarged aortic root, but 
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CLINICAL AND TECHNICAL CONSIDERATIONS IN PATIENT SPECIFIC AORTIC 
STENGRAFT DESIGN
Hubert Schelzig
Clinic for Vascular and Endovascular Surgery, Heinrich-Heine -University Düsseldorf, Germany
Hubert.Schelzig@med.uni-duesseldorf.de
Since experimental findings through the Ucrain 
surgeon Volodov utilizing EVAR, evolution in 
minmalinvasive aortic repair is still ongoing. The aim 
of this talk is not only to introduce technical but as 
well clinical prerequisites for successful repair of 
complicated aneurysm disease.
Planning strategy of custom made devices, central 
parts of equipment, shaping and specification 
of fenestrated and branched stengrafts will be 
discussed.
Finally, ongoing evolution and potential 
developments in minimal invasive aortic surgery will 
be presented.
AORTIC 
IS MINILAPAROTOMY FOR THE TREATMENT OF AAA STILL AN OPTION?
Mladen Gasparini
Izola General Hospital, Izola, Slovenia
mladen.gasparini@sb-izola.si
Key words: minilaparotomy, abdomnal aorta, 
aneurysm, surgery, open repair
For many years open surgery has been the gold 
standard for the treatment of patients with abdominal 
aortic aneurysm (AAA). But in the last 25 years 
endovascular methods have evolved remarkably so 
that the current guidelines suggest endovascular 
aneurysm repair (EVAR) as the method of choice for 
patients who meet the anatomical criteria and have 
a reasonable life expectancy. However, almost half of 
the patients who are candidates for AAA repair are 
unsuitable for endovascular repair. In these patients 
open surgery is still a valid option for abolish the risk 
of AAA rupture especially in younger, fit patients.
The standard open repair approach is done through 
a xypho-pubic laparotomy which causes significant 
trauma and has been associated with prolonged 
and potentially complicated postoperative recovery. 
To limit the surgical damage of total laparotomy 
different approaches through minimal incisions have 
emerged as an alternative. The most widely used are 
the midline longitudinal minilaparotomy, transverse 
minilaparotomies and the retroperitoneal approach.
A midline reduced laparotomy (minilaparotomy) 
through an 8 to 10 cm paraumbilical incision has 
been proposed 20-years ago by Cerveira as a feasible 
alternative to the total laparotomy for AAA repair. It 
offers sufficient exposure of both anastomotic sites 
through the manipulation and retraction of the small 
bowel. Studies comparing total laparotomy with 
minilaparotomy for the treatment of AAA found a 
significantly shorter period of recovery for the later 
without repercussion on the patient safety and 
clinical outcomes.
With the exception of patients with an iliac artery 
aneurysm extending to the external or internal iliac 
artery, minilaparotomy repair should be considered 




Acta Chirurgica Croatica Abstracts of Oral presentations
AORTIC
MINI-LAPARATOMIC ACCESS VERSUS LAPAROTOMY IN ABDOMINAL AORTIC 
DISEASE TREATMENT
Saleh Amro, I Gubarev, K Frolov, Y Belov
Pirogov City Hospital №1, Moscow, Russia
angiodoc@mail.ru
Keywords: mini-laparatomic access, Leriche 
syndrom, infrarenal abdominal aortic aneurysm,
We hypothesized that using mini-laparatomic 
approach would present a better outcome than total 
laparotomy in abdominal aortic disease treatment. 
Aim of the study is to improve the results of surgical 
treatment for Leriche syndrome and infrarenal 
abdominal aortic aneurysms by applying mini-
laparatomic access.
Material and Methods: 140 patients with infrarenal 
aortoiliac occlusion (TASC II C or D) and infrarenal 
abdominal aortic aneurysms were observed from 
January 2013 to September 2019. To perform 
an aorto-bifemoral bypass were compared the 
classic laparotomic access and mini-laparotomy. 75 
(46.4%) patients underwent reconstructive surgery 
on the abdominal aorta using full laparotomy 
access, 65 (53.6%) patients contained mini-access. 
The parameters of access (wound depth, angle 
of operative action, angle of inclination) were 
determined using intraoperative and CT data. 
Patients were approached according to demographic 
data and cardiovascular risk factors. Surgery 
and anesthesia duration, bleeding volume were 
compared. In postoperative period severity of pain, 
duration of intestinal paresis, in-hospital length stay 
were measured.
Results: Preoperatively estimated parameters 
allowed to perform the mobilization of infrarenal 
aorta, renal arteries, the Inferior mesenteric artery 
using mini-laparatomy access. Mean duration of 
mini-access surgery was 3:50 hours against 4:35 
hours using traditional laparotomy access. Average 
blood loss was 228 ± 120 ml in mini-laparatomy 
groupe against 472 ml in classic laparatomy group. 
Besides, there was a significant decrease of drugs 
volume used during anesthesia in mini-access group. 
Postoperative intestinal paresis duration in mini-
access group was 1.20 ± 0.05 days. Bowel paresis 
resolving in traditional access group was 2.20 ± 0.1 
days. In-hospital stay length during postoperative 
period in mini-access group was 4-7 days against 10-
14 days in classic laparatomy access group.
Conclusion: Mini-laparatomy access has significant 
advantages over standard laparotomy access to the 
abdominal aorta, provides minimal damage during 
surgery, ease the postoperative period.
AORTIC
VASCULAR ACCESS OPTIONS FOR TRANSCATHETER AORTIC VALVE 
IMPLANTATION
Daniel Unić
Dubrava University Hospital, Zagreb Croatia
Transcatheter aortic valve impmantation (TAVI) has 
emerged as an alternative option in patients with 
high surgical risk. Over the time a shift towards low-
risk patients has made “non-femoral” vascular sccess 
more attractive than transapical. Trans-subclavian, 
trans-carotid and direct aortic access are described 
and results discussed as well as transcaval.
AORTIC
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AORTIC RUPTURE WITH CONTAINED HEMATOMA: ENDOVASCULAR 
MANAGEMENT
Giselle Maria Ortiz, P Echeverria
Complejo Hospitalario Metropolitano, Panama City, Republic of Panama
giselleortizMD@gmail.com
Keywords: thoracic aorta, aortic rupture, 
endovascular repair
Non-traumatic aortic rupture is a challenging, very 
rare and life threatening disease. Rapid diagnosis 
and management are crucial to maximize patient’s 
survival. A 78-year-old female with history of 
arterial hypertension and recent diagnosis of 
myelodysplastic syndrome was being treated 
with antibiotics due to a lower respiratory tract 
infection for several days at other institution; when 
discharged, she developed sudden chest pain, 
dyspnea and hemodynamic instability. The patient 
was attended in the Emergency Room, where chest 
X ray showed a mass-like radiopacity displacing 
the mediastinum. Chest CT angiography revealed 
extravasation of contrast media due to rupture 
of descending thoracic aorta 1.9 cm after the left 
subclavian artery and a contained hematoma 
displacing the left lung’s superior lobe. Immediate 
and successful endovascular repair was made with 
Cook Zenith TX2 thoracic endograft (34×202 mm) 
under local anesthesia, without complications. In the 
postoperative period she required 2 RBC transfusions 
and complaints of intermittent and mild pleuritic pain 
where described by the patient. She was discharged 
4 days after, with no signs of neurologic deficits. 
Conservative management of hematoma was given; 
in control angioCT performed 1 month later there 
were no signs of endoleak and slight reapsortion 
of the hematoma was seen. She is currently stable 
and receiving hydroxyurea for the treatment of her 
leukemia. 
AORTIC
CASE REPORT OF AN EMERGENCY COMMON CAROTID TO SUBCLAVIAN 
ARTERY BYPASS GRAFTING AFTER TEVAR
Josip Figl, P Pavić, M Petrunić, Z Fiolić, A Crkvenac Gregorek, T Meštrović, I Šnajdar, D Halužan,  
M Davidović, I Brižić, I Škorak
Clinical Hospital Center Zagreb, Croatia
figlmd@gmail.com
Keywords: TAAA, TEVAR, vertebral artery, acute 
left arm ischemia, emergency common carotid to 
subclavian artery bypass grafting
We present a case of the need for urgent surgical 
revascularization of the left arm due to the 
development of an acute left arm ischemia after 
endovascular treatment of the saccular aneurysm 
of the descending thoracic aorta (TEVAR) that 
has covered the origin of the left subclavian 
artery. After the emergency common carotid to 
subclavian artery bypass grafting was done, the 
arm completely recovered. The reason for the need 
for revascularization is the aberrant origin of the left 
vertebral artery from the aorta instead of from the 
left subclavian artery. In cases like this, after TEVAR, 
the indication for the revascularization is much more 
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NEW HYPERTENSION GUIDELINES, THE EUROPEAN, THE AMERICAN AND 
THEIR SIGNIFICANCE
Reuven Zimlichman
Director of the Brunner institute for Cardiovascular Research, Tel Aviv University, Tel Aviv, Israel
zimlich@bezeqint.net
Development of treatment guidelines is based upon 
clinical evidence of morbidity and mortality change 
after therapeutic intervention. Generally, it is well 
accepted that the higher the blood pressure the 
higher morbidity and mortality. Thus, decisions to 
treat significantly increased blood pressure are well 
accepted, based on clinical studies in the 1950’s.
However, lower blood pressure and borderline levels 
and the prehypertensive range cause less morbidity 
and mortality and the beneficial effect of medical 
treatment in these subjects are more difficult to 
prove. While attempting to prove beneficial effect 
of medical intervention in borderline blood pressure 
levels, bigger and longer clinical studies have to 
be performed. In this group, cost- benefit ratio and 
number needed to treat are the parameters that have 
to be determined and affect treatment decisions. 
During the last decade, target blood pressure 
levels have been decreased gradually and the term 
Prehypertension (Although disputed) had been 
added. During the recent years, the ACCORD and 
the SPRINT studies have been performed, aiming to 
evaluate the effect of intensive therapy achieving 
lower blood pressure target levels. These studies, 
with somehow contradicting results, affected the 
hypertension guidelines and intensified the dispute 
about the recommended definitions of blood 
pressure target levels and the therapeutic approach. 
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CHARACTERIZATION OF STRUCTURE OF CAROTID PLAQUES AND ITS 
CLINICAL RELEVANCE
Pavel Poredoš
The University of Texas Health Science Center at Houston, Department of Advanced Cardiopulmonary Therapies and 
Transplantation, Houston, Texas, USA
pavel.poredos@kclj.si
Keywords: Circulating markers of atherosclerosis; 
cardiovascular risk; endothelial dysfunction; intima-
media thickness
The estimation of risk for atherosclerotic and 
cardiovascular events based only on the presence of 
classical risk factors is often insufficient. Therefore, 
efforts have been made to find markers that indicate 
the presence of preclinical disease in individual 
subjects: blood markers of atherosclerosis and 
preclinical deterioration of the arterial wall. Elevated 
levels of several inflammatory mediators have been 
found in subjects with atherosclerosis. Increased 
basal levels of cytokines, the cell adhesion molecules, 
selectins and acute-phase reactants such as high 
sensitive C-reactive protein (hsCRP), fibrinogen, and 
serum amyloid A are related to an increased risk of 
cardiovascular events. For clinical purposes, the 
most promising inflammatory biomarker appears 
to be hsCRP. In the last decade, markers of plaque 
stability and unstable coronary artery disease 
have been sought. Further, markers of endothelial 
dysfunction, like circulating molecules as well as 
indicators of functional deterioration of the arterial 
wall were identified. It was shown that endothelial 
dysfunction is closely related to different risk factors 
of atherosclerosis, and to their intensity and duration. 
Intima-media thickness measurement has emerged 
as one of the methods of choice for determining 
the anatomic extent of preclinical atherosclerosis 
and for assessing cardiovascular risk.Determination 
of markers of preclinical atherosclerosis improve 
individual risk determination and could influence the 
decision of a clinician to intervene with medication 
and to use more aggressive treatment of risk factors in 
high risk subjects and in patients with atherosclerotic 
disease.
CAROTID JOINT SYMPOSIUM MLAVS / CEVF
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CAROTID PRECLINICAL ATHEROSCLEROSIS PREDICTS FUTURE 
CARDIOVASCULAR EVENTS
Salvatore Novo
Università degli Studi di Palermo, Palermo, Italy
salvatore.novo@unipa.it
Several years ago, we demonstrated that risk factors 
and aging influence the appearance of asymptomatic 
carotid lesions, in particular the arterial hypertension, 
hypercholesterolemia and diabetes (Novo S et al. 
Advances in Vascular Pathology 1997, Elsevier Science, 
Excerpta Medica, Amsterdam, 1997, pp. 33-44).
Then, we demonstrated that preclinical carotid 
atherosclerosis enhances the global cardiovascular 
risk and increases the rate of cerebro- and 
cardiovascular events in a five-year follow-up (Novo 
S, Carità P et al. Atherosclerosis 2010; 211: 287-90) 
as well as in ten years follow-up (Novo S et al. Eur J 
Cardiovasc Prev Rehabil. 2010; 17: 514-8).
Moreover, sub-clinical ATS of carotid and MetS 
increase cardio- and cerebro-vascular events rate 
in a 20-years follow-up (Novo S et al. Cardiovasc 
Diabetol. 2013; 23: 155-62) and high plasma levels 
of endothelin-1 enhance the predictive value of 
preclinical atherosclerosis for future cerebrovascular 
and cardiovascular events in a 20-years prospective 
study (Novo G, Novo S et al. J Cardiovasc Med 2014; 
9: 696-701).
The value of preclinical carotid atherosclerosis on 
global cardiovascular risk stratification and events 
in a 10-year follow-up is confirmed also comparing 
the algorithms of the Framingham Heart Study, the 
European SCORE and the Italian ‘Progetto Cuore’ for 
the stratification of the global cardiovascular risk 
(Novo S, Carità P, Lo Voi A et al. J Cardiovasc Med 2019; 
20: 91-6). 
Recently, these data were confirmed by Palanca 
and al. (Subclinical atherosclerosis burden predicts 
cardiovascular events in individuals with diabetes and 
chronic kidney disease, Cardiovasc Diabetol. 2019; 18: 
93) and by Roumeliotis A et al. in patients with CKD (Ren 
Fail. 2019; 41: 131-8) on cardiovascular morbidity and 
mortality, and again in individuals with type 2 diabetes 
from the Rio de Janeiro type 2 diabetes cohort study 
(Cardoso CRL et al. Cardiovasc Diabetol. 2019; 18: 2), in 
the MESA Study (Mitchell CC et al. J Am Heart Assoc. 
2019; 8: e010875) as well as in a large asymptomatic 
American population (Sillesen H, Fuster V et al. Eur 
Heart J Cardiovasc Imaging. 2018; 19:1042-50). 
Moreover, it is well established that markers of 
inflammation may predict future cardiovascular events 
as we demonstrated for increased levels of soluble 
CD40L and cardiovascular risk in asymptomatic low-
grade carotid stenosis (Novo S et al. Stroke. 2005; 
36: 673-5), for increased levels of C-reactive protein 
and fibrinogen on the risk of vascular events in 
patients with NIDDM (Coppola G, Novo S. et al. Int J 
Cardiol. 2006; 106: 16-20), for increased markers of 
inflammation and infection influencing the outcome 
of patients with baseline asymptomatic carotid 
lesions: a 5-year follow-up study (Corrado E, Novo S. 
et al. Stroke. 2006; 37: 482-6) and for increased plasma 
levels of fibrinogen in acute and chronic ischemic 
coronary syndromes (Abrignani MG, Novo S et al. 
Cardiologia. 1999; 44: 1047-52).
On the other hand, these data are confirmed in the 
Women Health Study (Comparison of C-reactive 
protein and low-density lipoprotein cholesterol levels 
in the prediction of first cardiovascular events, Ridker 
PM et al. N Engl J Med. 2002; 347: 1557-65) in which 
the rate of CV events is higher in patients with highest 
levels of CRP or LDL-cholesterol or both. On the other 
hand Rosuvastatin, a statin that reduce consistently 
the levels of CRP, prevent vascular events in men and 
women with elevated C-reactive protein (Ridker PM et 
al for the JUPITER Study Group. New Engl J Med 2008; 
359: 2195-207).
Markers of inflammation are associated with plaque 
progression and instability in patients with carotid 
atherosclerosis (Ammirati E, Camici PG et al. Mediators 
Inflamm. 2015; 2: 2015-8) and drugs that reduce 
markers of inflammation such as Il-6 and CRP can be 
used as anti-inflammatory therapy as demonstrated 
in the CANTOS Study in which Canakinumab, in 
secondary prevention after AMI, reduced primary and 
secondary outcome (Ridker PM et al. for the CANTOS 
Trial Group. N Engl J Med. 2017; 377: 1119-31
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THE ROLE OF ULTRASONOGRAPHY IN THE MANAGEMENT OF CAROTID 
ARTERY DISEASE
Hrvoje Budinčević
Sveti Duh University Hospital, Zagreb, Croatia
hbudincevic@gmail.com
Keywords: Carotid artery disease, stroke, 
carotid ultrasonography, transcranial doppler 
ultrasonography, atherosclerosis
Carotid artery disease causes up to 15% of all 
ischemic strokes. Carotid artery disease might 
be easily accessed by ultrasonography (carotid 
ultrasonography for evaluation of extracranial 
portion of carotid arteries and transcranial Doppler 
ultrasonography for evaluation of large intracranial 
arteries). Other imaging modalities include: 
computed tomography angiography, magnetic 
resonance angiography and digital subtraction 
angiography. Ultrasonography of the carotid 
arteries is the modality of choice for diagnosis, 
monitoring and management of carotid artery 
disease patients. Carotid/ neck ultrasonography is 
routinely used for the estimation of carotid stenosis, 
plaque morphology and volume, and measuring 
intima-media thickness (useful biomarker for 
atherosclerosis). Carotid ultrasonography is also 
useful for assessment of non-atherosclerotic diseases 
such as cervical artery dissection and arteritis. 
Transcranial Doppler ultrasonography is a tool for 
evaluation of intracranial circulation, mostly for 
collateral circulation assessment, intracranial stenosis 
and emboli detection, and cerebral vasomotor 
reactivity. The management of carotid artery disease 
is mostly based on the severity of the disease (percent 
stenosis) and clinical presentation (asymptomatic vs 
symptomatic). Plaque morphology and integrity of 
intracranial circulation should be accounted in the 
decision-making process regarding management too. 
Current therapeutic options of carotid artery disease 
include medical/pharmacological treatment, carotid 
surgery and endovascular treatment (stenting).
CAROTID JOINT SYMPOSIUM MLAVS / CEVF
CAROTID DISEASE - WHERE WE STAND AND CHALLENGES FOR THE FUTURE. 
THE ASYMPTOMATIC CAROTID DISEASE DILEMMA
Jose Fernandes e Fernandes
Faculty of Medicine, University of Lisbon, Portugal
Lisbon Cardiovascular Institute / Hospital da Luz Torres de Lisboa, Lisbon, Portugal
jff@me.com
Stroke continues to be a health burden in modern 
societies and carotid bifurcation disease represents 
the cause of 25% of all strokes, which in approximately 
10-15% come from previously asymptomatic disease. 
These events could have been prevented through 
a greater awareness of appropriate symptoms of 
neurological and ocular dysfunction and a timely and 
properly conducted carotid intervention after the 
index event when the stroke risk is higher, plus early 
diagnosis in high-risk groups with asymptomatic 
disease through properly conducted selected 
screening for carotid are fundamental tools to reduce 
the ravage consequences of stroke.
Better management of risk factors, optimization 
of medical treatment contributed to diminish the 
atherosclerotic burden which in association with 
reduction of the number of asymptomatic patients 
being treated may explain the observed reduction in 
the number of carotid interventions being performed 
in the last decade.
After a brief review of the indications and timing 
of intervention in symptomatic patients through 
clinical examples from our series confirming the 
importance of early intervention after index event 
without increased neurological risk, plus comparison 
in published trials of the efficacy of  endarterectomy 
CAROTID JOINT SYMPOSIUM MLAVS / CEVF
24
Acta Chirurgica Croatica Abstracts of Oral presentations
(CEA) with stenting (CAS), we conclude that CEA 
continues to be the best choice for the appropriate 
treatment of symptomatic patients, preferably within 
the first week after the index neurological event with 
better outcomes than CAS.
Published guidelines from the ESVS and other 
scientific societies still recommend carotid 
intervention for asymptomatic carotid stenosis > 
70% provided the surgical risk is less than 3%, but 
this orientation has led a to an excessive number 
of unnecessary interventions. Better control of 
risk factors with optimization of best medical 
treatment has significantly reduced the risk of 
stroke in asymptomatic stenosis  and this reality 
has contributed to a reuction in the number of 
procedures performed in the last years. A better 
selection of patients with a higher risk group for 
stroke > 4 to 6% / yearly that may effectively benefit 
of carotid intervention can be achieved by carotid 
plaque structure analysis, better identification of 
clinical features such as diabetes and contralateral 
neurological symptoms, presence of appropriate 
hemispheric silent brain infarcts, embolization on 
transcranial Doppler examination thus providing 
better identification of this high-risk group that 
really could benefit from carotid intervention, either 
by CEA or CAS,  improving the selection of patients 
to intervention and reducing the excessive number 
of asymptomatic carotid stenosis being treated by 
invasive procedures CEA or CAS.
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THE INFLUENCE OF TECHNIQUE OF CAROTID ENDARTERECTOMY ON 
RESULTS IN SYMPTOMATIC PATIENTS
German Sokurenko, K Andreychuk, E Kiseleva, E Golovan’, V Kornev 
The Nikiforov Russin Center of Emergency Medicine, St. Petersburg, Russia
andreychuk@cvsurgery.ru
Keywords: carotid endarterectomy, symtomatic 
carotid stenosis
Objective: The eversion carotid endarterectomy 
(CEA) is one of the fist-line procedures for 
atherosclerotic carotid stenosis. However, procedure-
related haemodynamic changes and its following 
complications may prolong hospitalization and 
increase procedure-related morbidity and mortality. 
The typical, widely used, technique (T-CEA) requires 
to separate and invite destruction of carotid glomus. 
We are using the glomus-sparing technique (GS-CEA) 
because we surmise such would prevent procedure-
related haemodynamic changes. The aim of this 
study was to investigate the influence of the different 
eversion techniques in basic perioperative results 
and the incidence of postoperative complications.
Methods: Three hundred sixty-seven CEAs (254 
T-CEAs, and 113 GS-CEAs) were performed on 354 
patients over a seven-years period. The choice of CEA-
technique was not randomized. All of procedures 
were performed under general anesthesia with 
systemic heparinization. The majority of patients 
in both groups be treated with antiplatelet drug 
continuously. Perioperative course, blood pressure 
deviation, antihypertensive drug demand and the 
incidence of postoperative complications, as well as 
re-stenosis rate were evaluated.
Results: No significant differences in the number 
ischemic complications (1.6 % vs. 0%; 0.052), the 
restenosis rate (3.4% vs. 2.6%; 0.087), but a difference 
in favour for T-CEA-group in the length of the surgery 
(56.5±14.9 minutes vs. 62.0±11.5 minutes; 0.020) and 
in the time of clamping (12.1±4.9 minutes vs. 17.3±4.5 
minutes; 0.031) were revealed. At the same time, the 
other criteria disclosed the advantages of thereof in 
the prevention of postop hypertension (p=0.008) and 
as a natural result, in the amount of postop drainage 
(0.011), local hemorrhage (0.009), incl. re-op (0.001) 
and re-intubation (0.001) cases. In GS-CEA-group the 
rate of postoperative brain edema and its following 
encephalopathy were significant (0.017) lower too. 
Eventually, the total number of postop complications 
was significantly less in the GS-CEA (0.011).
Conclusion: The results of this study suggest that 
glomus-sparing eversion endarterectomy may be 
worthy alternative to typical procedure for prevention 
of postoperative complication.
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SELECTED ASYMPTOMATIC PATIENTS SHOULD BE REVASCULARIZED: 
MEDICAL THERAPY MUST BE OPTIMIZED
Christos Liapis
Athens Medical Center, University of Athens, Greece
liapis@med.uoa.gr
The identification/selection of appropriate patient 
subgroups with asymptomatic carotid artery 
stenosis and the performance of prophylactic 
carotid endarterectomy (CEA)/carotid artery stenting 
(CAS) exclusively on these asymptomatic patient 
subgroups is currently one of the “hottest” topics in 
vascular surgery. It is now clear that offering CEA/
CAS to asymptomatic carotid patients based only 
on the degree of carotid stenosis is unjustified and 
scientifically flawed. On the other hand, offering only 
best medical therapy to every asymptomatic patient, 
irrespective of certain high-risk criteria (such as the 
detection of microemboli by transcranial Doppler, 
intraplaque hemorrhage, silent embolic infarcts on 
brain computed tomography/magnetic resonance 
imaging, elevated biomarkers, family history), is 
equally wrong. The validation of specific measures to 
identify those asymptomatic patients at high risk for 
developing symptoms is crucial to achieve optimal 
use of carotid interventions and avoid wasting 
stroke prevention resources. At the same time the 
optimization of medical therapy including tests to 
identify patients’ resistance for antiplatelets and 
intolerance to statins is of paramount importance. 
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DETERMINATION OF INDICATIONS FOR SURGICAL TREATMENT WITH A 
COMBINATION STENOSIS AND TORTUOSITY OF THE INTERNAL CAROTID 
ARTERY IN ACUTE ISCHEMIC STROKE
Stanislav Ordynets, Ivan Dudanov 
Mariinsky Hopital, Saint-Petersburg, Russia
ordynets.spb@me.com
Keywords: Acute stroke, internal carotid artery, 
carotid stenosis, endarterecromy
Ischemic stroke (IS) is one of the main reasons of 
morbidity, mortality and disablement all over the 
world. The study of the acute phase of disease 
has fundamental meaning of medical assistance 
development for the stroke sufferers.
The palindromia risk for stroke sufferers amounts 
from 5 to 20 percent within the first 30 days (the risk 
factors are severe stenosis, kinking, unstable plaque, 
floating thrombus).
Study purpose: to prove the surgical treatment 
effectiveness of the combination of stenosis 
and carotid artery pathological deformation in 
comprehensive rehabilitation of patients in acute 
phase of ischemic stroke.
Materials and techniques: From 281 patients 
operated for acute IS, 112 (39,9%) had associated 
atherosclerotic stenoses with kinking of the internal 
carotid artery.
In case of combined pathology the risk of recurrent 
stroke is rising steeply. In spite of modern level of 
carotid surgery, the risk of conversion from the 
ischemic lesion into the hemorrhagic infarction focus 
remains as the main argument to delay operation.
There were 3 groups defined: I group – patients, 
who had IS or transient ischemic attack and who 
were operated within 2 weeks from the beginning of 
acute cerebrovascular accident – 47 (42%) patients, 
31 (66%) male, 16 (34%) female were among them. 
II group – patients, who had IS or transient ischemic 
attack and who were operated from 2 to 4 weeks from 
the beginning of acute cerebrovascular accident – 10 
(8,9%) patients, 8 (80%) male, 2 (20%) female were 
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among them. III group – patients, who had IS and 
who were operated later than one month from the 
beginning of acute cerebrovascular accident – 55 
(49,1%) patients, 34 (61,8%) male, 21 (38,2%) female 
were among them.
For the operative treatment preference was given 
to the method of the resection of internal carotid 
artery with its redressement and reimplantation 
upon specific indications. Contraindications to this 
surgery were: intimal proliferation in the area of 
maximum bending – “septal kinking” and expressed 
degenerative changes in the area of this bending, 
which impede to spread vessel adequately during 
redressement attempt or microaneurysmal changes 
in the arterial wall. In case of kinking with septal 
stenosis the resection of the crimp zone with 
anastomosis end to end was perfirmed.
Research results: For surgery safety evaluation 
perioperative complications were taken into account, 
first of all from the position of the evaluation of the 
risk of hemorrhagic transformation of ischemic stroke 
after restoration of blood flow through the early 
carotid reconstruction, made in different periods 
of acuity. Results evaluation was made in condition 
of such characteristical identity of the groups as 
sex, age, co-morbidity, nature of kinking, degree of 
stenosis, severity of neurological deficit, etc.
The positive dynamics of neurological symptoms 
was observed in group I for 46 (97,9%) patients, in 
group II for 8 (80%) patients, in group III for 43 (76,2%) 
patients. It should be noted that full recovery had 
almost every third patient in group I and II.
The neurological complications had 1 patient 
(group III) and lethality had 1 patient (group III). 
Hemorrhagic transformation of brain infarction focus 
after carotid artery reconstruction wasn’t observed in 
our research.
To determine the operation time, the severity of 
neurological disease and co-morbidity should be 
taken into account. For the patients with severe 
neurological deficit and for patients who had IS, 
early reconstruction of carotid artery increase the 
efficiency of the functional recovery, broken during 
stroke due to improved cerebral perfusion and 
activation of neuroplasticity in the early stages of 
acute cerebral ischemia (p<0,05). The beneficial 
effect after reconstructive surgery on carotid artery 
of patients with moderate or severe neurological 
deficit is more pronounced than in the absence of 
neurologic symptoms or when the minor severity.
Taking into account international recommendations, 
in the acute period of IS the reconstruction of carotid 
artery with the value of the NIHSS scale more than 12 
wasn’t performed. It was determined that the most 
effective terms of reconstructive operations on carotid 
arteries are the first 2 weeks from the beginning of 
the development of the brain catastrophe.
Conclusion: Considering the analysis of frequency of 
postoperative complications, we determined that the 
patients with combined stenosis and kinking of the 
internal carotid artery who were operated without 
significant delay, have higher probability of the 
complete regression of neurological symptoms and 
consequently, disability reduction and restoration 
of the original employability in comparison with 
patients who were operated it terms of 4 or more 
weeks after the first symptoms appearance.
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ARTERIAL EVALUATION IN PATIENTS WITH VENOUS LEG ULCERS
Patrick H Carpentier
Department of Vascular Medicine, Grenoble – Alpes University, France
patrick.carpentier@univ-grenoble-alpes.fr
In spite of the many progresses in the management 
of chronic venous disorders, the annual incidence 
of leg ulcers remains as high as 0.5 to 0.7% in the 
population of industrialized countries, and their mean 
healing time close to 6 months. Their occurrence 
in the elderly patients makes it likely that a large 
proportion of these patients also have coexistent 
clinical or subclinical significant peripheral arterial 
disease, with an increasing proportion of mixed or 
multifactorial ulcers in the recent series. 
Even if endovascular correction of superficial vein 
refluxes and deep vein obstruction has improved 
our capabilities in treating these patients, the 
compression therapy remains the mainstay of their 
treatment, and it has to be adapted or even can be 
contra-indicated in case of coexisting untreatable 
arterial disease.
This situation makes it important to detect and 
quantitatively assess the severity of arterial disease 
in all patients with leg ulcers, even if their venous 
origin seems to be clear. Ankle Brachial Index is the 
test recommended by most guidelines for such an 
arterial evaluation, but its measurement in patients 
with leg ulcers is not without pitfalls. 
This presentation will discuss all these aspects, as 
well as alternative arterial tests for the evaluation of 
such patients.
CHRONIC WOUNDS
NO-OPTION CLI: NOVEL WAYS OF TREATMENT 
Nicos Angelides 
University of Nicosia, Cyprus, Cardiovascular Surgical Unit Nicosia General Hospital, Nicosia, Cyprus 
n_angelides@hotmail.com
Recently, it has been demonstrated that the use of 
stem cells alone or in combination with gene therapy 
can provide benefit in terms of relieving rest-pain 
and healing ischaemic ulcers. The use of stem cells is 
based on holistic medicine which considers a person 
as a functional unit. By activating the body’s ability of 
self-regulation this may allow the body to use its own 
powers of self-healing to overcome the problem. 
Stem-cell therapy utilizes the following steps: (a) 
Harvesting of stem cells. (b) Separation of stem 
cells and replacement of the damaged cells by stem 
cells). (c) Activation of stem cells. (d) Administration 
of stem cells through infusion to the patient. (5) 
Improvement of patient’s condition (less pain, better 
healing of ulcerations, better standing and walking. 
Bone marrow aspiration is the usual method of 
harvesting the stem cells. This can be performed from 
the greater tuberosity during shoulder arthroscopy 
or from the iliac bone. Therapeutic administration of 
stem cells can also be performed by harvesting from 
adipose tissue and umbilical cord. 
Arteriogenesis can be considered as the 
transformation of pre-existent collateral arterioles 
into functional collateral arteries. Several studies have 
shown that cellular mediators and tissue-specific 
chemokines may facilitate selective recruitment of 
bone marrow stem and progenitor cells influencing 
arteriogenesis and restoring blood flow in limbs, 
retina and myocardium. It has been demonstrated 
that the injection of bone marrow mononuclear cells 
(BM-MNCs) significantly improves pain-free walking 
time, rest pain, and tissue oxygen pressure, on 
average 6 months after treatment, whereas injection 
of peripheral blood mononuclear cells did not lead 
to similar significant effects. Recent discoveries 
showed that stem cells have been detected in organs 
such as brain and muscles that were thought to lack 
regenerative potential. Also, resent discoveries on 
stem biology have shown that organ-specific stem 
cells appear to display much more plasticity and can 
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differentiate from one tissue into a variety of unrelated 
cell types and tissues. Also, it has been demonstrated 
that human embryonic stem cells can be isolated 
from early fetuses and differentiated in vitro into a 
wide variety of cell types. Finally, it has been found 
that regions of severe oxygen deprivation (hypoxia) 
arise in tumors due to rapid cell division and aberrant 
blood vessel formation. 
In parallel, gene therapies represent a new field for the 
treatment of a wide variety of inherited and acquired 
human diseases. Gene therapy can be defined as the 
genetic modification of cells to produce a therapeutic 
effect. Such modification can be carried out either 
in vivo or in cultured cells ex vivo, which then are 
administered to the patient. Progress in the areas 
of gene therapy implies (1) The genes’ discovery, (2) 
The vector’s development, and (3) The transgene 
regulation. However, much work remains to be done 
before human gene therapy is beyond any doubt 
safe and effective, In particular, vectors are needed 
so that they can safely target specific cell types. These 
vectors must be easily produced at high titers and in 
large quantities. Also devices are needed in order 
to efficiently deliver vectors in vivo. Finally, a better 
understanding is needed of normal cell biology and 
of the biochemical and genetic responses of human 
diseases. Nowadays, are in progress combinations 
of gene and stem therapies and several pre-clinical 
studies are on the way. It seems that combination 
of these two methods is useful in patients with poor 
outflow and other comorbidities which do not allow 
any revascularization procedure to be carried out, as 
well as in patients who had previously several failed 
therapeutic attempts. These patients represent a 
population where a high rate of limb loss and death 
are occuring. 
Like many novel therapeutic approaches, gene- and 
stem-cell therapies raise a number of important 
ethical issues and concerns. Some are common to 
any new therapy involving human experimentation. 
Others are more unique and apply to specific 
methods used in gene- and stem-cell therapies. 
Nevertheless, such ethical debates will continue to 
represent an important determinant of the progress 
and use of novel therapies in the future.
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VASCULAR SURGEON AND CHRONIC WOUNDS
Ana Jović
Clinical Hospital “Sveti Duh”, Zagreb, Croatia
ana.lamza7@gmail.com
Chronic wounds represent a significant burden to 
patients, health care professionals, and health care 
system. Internationall studies estimate the prevalence 
of current chronic leg ulcers to be approximately 
1% and up to 9.8% for both healed and nonhealed 
ulcers in persons older than 70 years. Of these, most 
(approximately 80%) are thought to be caused by 
venous disease rather than arterial disease. Common 
chronic skin and soft tissue wounds include the 
arterial ulcer, the venous stasis ulcer, the diabetic foot 
ulcer, the pressure ulcer. 
Ulceration due to vascular causes is often 
multifactorial and can be caused by both arterial and 
venous disease. Hypertension and atherosclerosis 
of the peripheral vessels lead to arterial disease 
associated with ischemic ulcers. Chronic venous 
insufficiency and the resulting venous hypertension 
cause venous ulcers. Vasculitis such as Buerger 
disease (thromboangiitis obliterans) or Takayasu 
disease can also be associated with ulceration. 
The great majority of vascular ulcers are chronic or 
recurrent. They cause a considerable amount of 
morbidity among patients with peripheral vascular 
disease, including work incapacity. Additionally, these 
nonhealing ulcers place the patient at much higher 
risk for lower extremity amputation. Surgical therapy 
of vascular ulcers may be accomplished by a number 
of methods; tailor the choice to fit both the patient’s 
and surgeon’s expectations. Revascularization may 
be most appropriate in one patient and amputation 
with rehabilitation most suitable in another. Surgery 
to correct venous reflux does not appear to improve 
ulcer healing, though it may reduce the recurrence of 
problem wounds. 
Surgical therapy is an integral part of the treatment 
of nonhealing wounds. Wounds with necrosis or 
infection usually require debridement or incision of 
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APPLICATION OF COMPRESSION THERAPY IN THE TREATMENT OF 
LYMPHEDEMA
Tanja Planinšek Ručigaj1, Sandra Marinović Kulišić2
1Dermatovenerology Clinic, University Clinical Center Ljubljana, Slovenia
2Clinical Hospital Center Zagreb, Dermatovenerology Clinic, Faculty of Medicine, University of Zagreb, 
  Zagreb, Croatia
sandra.marinovic@zg.htnet.hr 
Keywords: lymphedema, primary, secondary, 
compression therapy
Lymphedema is a condition of extremities swelling 
due to lymphatic hypoplasia (primary) or obstruction 
or injury to the lymphatic vessels (secondary). There 
is abnormal accumulation of interstitial fluid rich in 
protein, which increases the intercellular plasma 
oncotic pressure and leads to further accumulation 
of fluid. It also contains wather, blood cells and 
hyaluronic acid. Symptoms and signs are firm, hard 
and fibrous edema of one or more extremities. 
With persistent treatment and application of 
preventive measures the symptoms can be weakened 
and slowed down and the advancing of the illness 
can be completely stopped. In the last few years, a 
new classification has been developed, dividing 
primary lymphedema according to phenotypes and 
in the same cases by genetics where the genes are 
know, to secondary lymphedema. 
Compression therapy is part of the vein surgery 
treatment and lymphedema. The pressure under the 
bandages has to exceed the intravenous pressure 
wich is to higher in standing position. Different 
compression material different works on speed 
of reducing the oedema, on venous refluxes, on 
venous pump, on ambulatory venous hypertension, 
on microcirculation and on lymphatic drainage. 
Compression material with high stiffness is more 
effective to prevent and reducing oedema than 
compression with low stiffness.
Inelastic materials or short strech bandages system 
faster reducing the oedema, faster and beter reducing 
the venous refluxes in superficial and deep venous 
system, better promoting the venous pump, faster 
decreasing of ambulatory venous hypertension, 
improving the microcirculation and promoting and 
improvement the lymphatic drainage with increased 
lymphatic contractions. Stiff compression cause 
intermittent venous occlusion during walking and 
so impeding venous reflux. The inleastic multi layer 
bandages system - materials have higher efficacy 
than long strech materials. Intermittent compression 
enhances arterial flow too. Reducing the oedema 
is enhanced by movement of calf and foot, micro 
massage under the under-padding compression 
materials, with arterial pulsation and respiration 
too wich working on lymphangions. Long stretch 
bandages and compression stockings wich have 
extensibility more than 100% performing moderate 
working pressure but they are easier to apply by 
patient alone or his relatives. Applaing of short 
stretch bandages request trained staff. Bandages 
applied with excessive tension can cause tissue 
damage leading to necrosis at the patients with 
unrecognized artherial occlusive disease. So, before 
applaing the compression ancle brachial index have 
to be measurement. 
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CHRONIC SURGICAL WOUNDS AND BIOFILM
Nastja Kučišec-Tepeš, Sandra Marinović-Kulišić
Academy of Medical Sciences of Croatia, Croatian Wound Assosication, Zagreb, Croatia
davorin.tepes@gmail.com
Keywords: chronic surgical wound, infection, biofilm
The notion of surgical site infection (SSI) implies the 
infection of the incision or of the organ or organ 
space, as a consequence of surgical intervention. It 
develops up to 30 days aft er surgery or up to one 
year in the insertion of prostheses or implants.
An acute wound can develop into a chronic 
one in every phase of healing, most frequently 
as a consequence of infection. Measures which 
facilitate healing and prevention of infection are 
good hydration, oxygenation and absence of pain. 
Impediments to healing are numerous. They are 
the result of interrelationship of the comorbidity of 
the host, extrinsic factors such as the characteristics 
of bacteria or fungi, and their virulence factors, 
predominantly the biofilm. Extrinsic risk factors in a 
surgical patient appear in the pre-operative, intra-
operative and post-operative period, along with 
other factors related to localisation and type of 
operation. 
Wound infection is a continuous process which 
develops in several phases, and it is defined by the 
relationship of microbes and the host, along with 
belated or inefficient preventive measures.
The infection of acute and chronic surgicalers by 
clinical symptoms, course and consequences, as 
well as on the level of pathophysiological-molecular 
processes which are determined by the biofi lm and 
bacterial multiple resistance.
The presence of bacteria in the wound and in the 
tissue includes quantity, variety, virulence, mutual 
interaction, along with a synergy of action in relation 
to the host. 
The reservoir and source of etiologic agents of 
infection is primarily the physiological flora of the 
skin. Activity of bacteria in the wound depends on the 
quantity of agents, and type and quantity of virulence 
factors. We differentiate several types of virulence 
factors which are signifi cant in the development 
of infection. These are factors connected to the 
bacterial cell wall such as hydrophobia, adhesins and 
biofi lm, followed by excretory ones such as enzymes 
and exotoxins and endotoxins.
Biofilm is a complex community of aggregated and 
adhering bacteria, connected with a self-producing 
extracellular polysaccharide matrix. The removal 
of biofilm is extraordinarily complicated. A relative 
success can be obtained by debridement along 
with the application of dressings with anti-biofilm 
activity. The goal of the physiological healing of 
the surgical incision is the re-establishment of 
the integrity of tissue and function, along with a 
cosmetically acceptable appearance of the scar. A 
basic supervision of the surgical incision includes 
the host, the environment and endogenous flora. 
The strategy of wound care and treatment relies 
on the establishment of cell balance and return of 
the wound into a healing phenotype along with an 
action on the etiological agents of infection.
Infection of the wound is multifactorial, and the 
procedures of prevention and treatment are multi-
modal and must be combined and repeated. In this 
process, a certain role is played also by antiseptics which 
are bactericidal, as well as biofi lm-active substances, 
especially those incorporated in up-todate dressings.
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THE EXPERIENCE OF SUCCESSFUL USE OF NEGATIVE-PRESSURE WOUND 
THERAPY IN PATIENTS WITH INFECTIOUS COMPLICATIONS AFTER SURGERY 
ON THE AORTO-ILIAC AND FEMORAL-POPLITEAL SEGMENTS
Saleh Amro, I Gubarev, K Frolov, Y Belov, L Magnitskiy, K Rybakov
City Clinical Hospital №1 named after N.I. Pirogov, Moscow, Russia
angiodoc@mail.ru
Keywords: Negative-pressure wound therapy, 
NPWT, infectious complications
The aim is to study the effectiveness of Negative-
pressure wound therapy (NPWT) in patients with 
infectious complications after surgery on the aorto-
iliac and femoral-popliteal segments.
Materials and Methods: We have observed 22 
patients who formed infectious complications 
with postoperative suppuration of wounds after 
performing reconstructive surgeries on the lower 
limb arteries. The study group included 18 (82%) men 
and 4 (18%) women. 11 (50%) patients had diabetes 
mellitus, 10 (45%) patients were obese. 17 (77%) 
patients were performed femoral-popliteal bypass, 
5 (23%) patients underwent aortofemoral bypass 
surgeries.
In most cases (77%), infection has occurred in the 
upper-third hip. For all of study patients was executed 
surgical treatment of purulent focus in post-operative 
wounds, using NPWT after the development of 
infectious complications. Further to all the patients 
received antibiotic therapy according to the results 
of bacteriological sowing from the wound. Stage-
by-stage sanctions were fulfilled every three days. 
Having inflammation symptoms relieved, bacterial 
contamination reduced, repeated surgical treatment 
with excision of affected tissues was performed.
Results: After NPWT, the majority of patients (91%) 
had complete wound cleansing. In 1 (4.54%) case 
after long-term therapy from the distal anastomosis 
area of the femoropopliteal bypass developed an 
arrosive bleeding, that was demanded to remove 
synthetic prosthesis.
Conclusion: NPWT is a safe and effective method of 
treatment infectious complications after surgeries on 
the aorto-iliac or femoral-popliteal segments.
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INTERDISCIPLINARY APPROACH TO THE PATIENT WITH HARD TO HEAL 
VENOUS LEG ULCER – CASE REPORT
Tamara Sinožić1, J Kovačević1, S Suknaić2, K Novačić2
1Family medicine practice Tamara Sinožić, MD, PhD, Mošćenička Draga, Croatia
2Outpatient clinic VeNeS Zagreb, Croatia
sinozictamara@gmail.com
Keywords: compression therapy, endovenous laser 
ablation, hard to heal wounds, venous leg ulcer
Aim: to present a combined treatment of hard to heal 
venous leg ulcer (VLU): topical with wound dressings, 
compression therapy and endovenous laser ablation 
(EVLA) after the wound healed to prevent recurrence.
Method: a 78-year-old patient comes in for visit due 
to a 4-year-old leg ulcer, 150 cm2 in size, on the left 
lower leg that shows no signs of improvement despite 
local therapy and long stretch bandage compression 
therapy. Dressing changes are done 3 times a week 
at the family doctor’s practice or by patient itself with 
regular dermatologist check-ups. Comorbid diseases: 
arterial hypertension and osteoporosis.
The VLU was verified clinically and with duplex 
ultrasound, insufficiency of Great Saphenous Vein, 
followed with Ancle Brachial Pressure Index (ABPI) 
measurement, right leg 1.22, left leg 1.19. The 
formation of biofilm at the wound bed was clinically 
evaluated and debridement and dressing changing 
were done regularly with Enhanced Hydrofiber 
Dressing with Silver and Strengething Fibre, as well 
as with secondary polyurethane foam dressing with 
the application of multi-component compression 
system of short stretch bandages.
Results / Discussion: the wound healed completely 
within a period of 25 weeks in the continuation of 
the treatment, compression stockings 23-32 mmHg 
are being applied. A one year after VLU healed EVLA 
was conducted to prevent recurrence. The procedure 
went without complications.
Nine-month monitoring period shows no signs of 
relapse.
Conclusion: venous leg ulcer is successfully 
treated with the application of combined local and 




Acta Chirurgica CroaticaAbstracts of Oral presentations
VENOUS
SEALING IN VARICOSE VEINS
Oguz Karahan
Department of Cardiovascular Surgery, School of Medicine of Dicle University, Turkey
oguzk2002@gmail.com
Keywords: Varicose veins, treatment, glue 
application, recent advances
The cyanoacrylate glue application for different kind 
of vascular diseases such as vascular anastomoses, 
occlusion of aneurysms and vascular fistulae was 
recommended since the 1960s. Especially, first 
clinical vascular occlusion series with cyanoacrylate 
was reported after the 1970s. However, the clinical 
usage of cyanoacrylate for the treatment of lower 
extremity varicose disease gain popularity in the last 
decade.   
The previous popular methods for endovenous closure 
of varicose veins were depended on endothermal 
methods such as laser and radiofrequency ablation 
that requires tumescent anesthesia. According to 
presented results from scientific reports glue seems 
to be effective in lower extremity varicose disease 
that can not be treated with medical therapy and 
being non-thermal as not requiring tumescence is an 
extremely popular technique. However, the industry 
trying to develop some new strategies for taking this 
technique more useful and solving some confusing 
problems about he residual material, diffuse 
distribution, and postoperative progress. 
Recently studies focused on developing more elastic 
and soft glue options and also presenting good 
alternatives for diffuse and easier delivery techniques. 
It seems to be glue treatment of varicose veins will 
become more popular with further advances. 
VENOUS
INTERVENTIONAL TREATMENT OF DEEP VENOUS THROMBOSIS. WHICH 
PATIENT?
Oguz Karahan
Department of Cardiovascular Surgery, School of Medicine of Dicle University, Turkey
oguzk2002@gmail.com
Keywords: Deep venous thrombosis, post-
thrombotic syndrome, pharmacomechanical 
thrombectomy
Despite the use of anticoagulant therapy, the post-
thrombotic syndrome (PTS) develops within 2 years 
in approximately half of the patients with proximal 
deep-vein thrombosis. Recent studies claimed that 
quality-of-life scores of moderate symptoms patients 
with PTS were reported as lower than diabetes, 
arthritis, and chronic lung disease. Thus, more recent 
alternative interventional therapies to reducing 
thrombosis burden for avoiding the progression of 
PTS in patients with deep venous thrombosis (DVT) 
were developed. However, clinical data about these 
pharmacomechanical thrombectomy techniques still 
insufficient and there is no exact consensus about 
application time and selection of technique. 
Goals of invasive techniques can be listed as 
diminishing the severity and duration of extremity 
symptoms, prevent pulmonary embolism and also 
PTS, and minimize the risk of recurrent venous 
thrombosis. In current presentation we aimed 
to discuss the possible cost effectivity of these 
interventional techniques and patient selection 
criteria for pharmacomechanical thrombectomy.
As the results of recent data further investigations 
may helpful for the clarifying the pathophysiological 
basis of PTS and define alternative applications to 
reduce progression or alleviate disabling symptoms. 
According to the findings from these investigations, an 
algorithm for management of pharmacomechanical 
thrombectomy applications should be determined.
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INPACT OF ENDOVASCULAR MANAGEMENT OF ARTERIOVENOUS FISTULA 
MALFUNCTION IN PRESERVING HEMODYALISIS ACCESS
Lovro Tkalčič1, S Živčić-Ćosić1, S Kovačić1, S Knežević1, B Budiselić1, D Miletić1, D Kuhelj2
1Clinical Hospital Center Rijeka, Rijeka, Croatia
2University Medical Center Ljubljana, Ljubljana, Slovenia
lovro.tkalcic@gmail.com
Key words: arteriovenous, fistula, endovascular, 
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Background: To present our initiative and 2-year 
follow-up resolving arteriovenous fistula (AVF) 
malfunction in 45 patients.
Materials and methods: From July 2015 till November 
2019, 45 patients with dialysis access related 
complications, most commonly inadequate blood 
flow rate during dialysis, arm swelling, pain during 
dialysis, and shortening of dialysis sessions due to 
clotting were presented to our department and 
underwent endovascular management.
Results: Of 45 patients admited to our Department, 
37 pts had indication for endovascular treatment due 
to stenosis or occlusion of AV fistula, with tehnical 
success in 33 patients (89%) of cases. We did 6, 12 ad 24 
months follow-up, considering kidney trasnplantation 
or patent AVF as success of our treatment.
After 6-months, all patients with follow-up (7/7) 
treated with drug eluting baloon angioplasty (DEB) 
had patent AV-fistula and one patient recieved 
kidney transplant, compared to only 9/17 (53%) 
patent AV fistulas in patients treated with plain old 
baloon angioplasty (POBA). At 1-yeat follow up, one 
patient in DEB group recieved kidney transplant and 
remaining 3 out of 5 patients had patent AV fistulas, 
while POBA group patients had one restenosis and 
patent AVF in remaining 8 patients. Loss of patients 
after 2 years left 2 patients in DEB group to follow-up, 
with one trombosed AVF, while 3 out of 5 patients in 
POBA group showing patent AVFs.
Conclusion: Our close multidisciplinary collaboration 
was successful in reducing vascular access 
complications, lowering dialysis patients’ morbidity, 
and increasing the percentage of patients with a well-
functioning AV fistula for long-term hemodialysis 
treatment, and serving as bridging towards 
transplantation. In addition, possible better results 
with DEB should be confirmed in larger cohort.
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SURGICAL TREATMENT OF TUMORS IN BIG VEINS
Tankut Akay
Baskent University, Ankara, Turkey
tankutakay@gmail.com
Introduction: Thrombus and tumours extending into 
the inferior vena cava (IVC) in 10% of cases at diagnosis 
and up to the right atrium in 1% of cases In this specific 
scenario, clinical presentation is often characterised 
by acute cardiovascular failure o major systemic 
symptoms due to the concomitant presence of locally 
advanced bulky tumour, caval involvement, and/or 
distant metastases. Although prognosis is usually poor, 
selected patients may benefit from surgical treatment 
in the context of a multimodal management . We aimed 
tos hare our experience in this challenging situation. 
Methods: We retrospectively analyzed 19 patients 
with thrombus or tumours in big veins who 
underwent surgery. There were 6 renal cell ca (5 type 
I and type 3), 2 leiomyoma and 1 leiomyosarcoma 
in inferior vena cava, 1 lipoma in subclavian vein, 2 
tumour infiltration into superior vena cava and 7 
patients with tumour infiltration to vena cava inferior. 
Mortality and technique was discussed. 
Results: In all patients tumours were extracted. 
(videos) 4 patients were treated with dacron patch 
plasty with dacron, 12 patients with primary repair, 
3 patients with graft interposition (PTFE, spiral vein 
graft and dacron ). In 4 patients cardiopulmonary 
bypass and in one patient total circulatory arrest 
was required. Mean follow up period was 28 months. 
There wewre 3 mortality beacuse of malignity.
Conclusion: Although the most appropriate or 
efficacious surgical technique remains unclear, it 
should be selected judiciously for each case based 
on the level of tumour thrombus.. Future research 
must endeavour to carefully design prospective 
comparative studies with experimental designs 
and use of appropriate controls to ascertain which 
surgical technique offers the best outcomes.for this 
challenging group of patients. 
VENOUS
ENDOVASCULAR TREATMENT OF THORACIC CENTRAL VEIN OCLUSION 
STENT (PREVIOUS INTERVENTION) WITH A PARALLEL STENT – CASE REPORT
Thais Duailibi, C. A. Schreiner, M. B. Santarosa, E. E. Joviliano
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, Brazil
tduailibi@gmail.com
Keywords: central venous obstruction, endovascular 
treatment, stenting, recanalization, parallel stents
Introduction: Superior Vena Cava Syndrome is a 
frequent complication in patients in hemodyalisis 
who have had previous venous catheter accesses. 
Treatment options include balloon angioplasty, 
stenting, venous bypass or fistula ligation. 
Recanalization of occluded central vein is difficult 
and the endovascular treatment have frequent and 
rapid recurrence, requiring early reintervention. 
The objective of this study is to report a case of 
recanalization of thoracic central vein obstruction 
with an occluded previous stent with a parallel 
position stenting.
Case report: 65-year-old male, with chronic kidney 
disease in hemodyalisis, with brachiocephalic 
arteriovenous fistula (AVF), with edema and pain in 
the left upper limb, collateral circulation (Superior 
Vena Cava Syndrome). History of previous venogram 
with central vein critical stenosis and treated 
with stenting. Performed new intervention for 
recanalization and angioplasty with stent parallel to 
the previous stent with good flow and regression of 
the symptoms.
Conclusion: Endovascular techniques allow several 
reinterventions in the same territory. The case 
presented was an example of immediate success after 
local interventions. The development of new devices 
and the improvement of endovascular techniques 
provide less invasive approaches to complex cases.
VENOUS
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FLUOROSCOPY GUIDED BLOCKED SAPHENOUS VEINS SCLEROTHERPY 
(FGBSS), ANOTHER POINT OF VIEW
Louay Altarazi1,2, A Hassan2, M Hassino2
1Damascus University, Syria
2Varicose veins & vascular clinic, Salhieh Tower, Damascus, Syria
Keywords: Saphenous, Varicose veins, Sclerotherapy
Objective: An ideal method treating GSV 
incontinence should be effective, safe ,inexpensive, 
painless and ambulatory, it could treat associated 
varicose veins and pelvic congestion syndrome at 
same session.
FGBSS looks comparable to this ideal, we think that 
it is worthwhile to present our team experience, 
it includes never seen before videos and images 
of Saphenous veins anatomy and its reaction to 
sclerothrapy.  
Methods: Between march 2008 and march 2012: 62 
patients (69 legs: 7 bilateral) underwent FGBSS for 
GSV varicose veins 
Associated simultaneous procedures: 
• 6 LSV and 7 perforators sclerosis, 13 branches 
sclerosis 
• 8 pelvic congestion syndrome and 1 varicocele 
embolizsation 
• Under ultrasounds guidance, just below the knee 
GSV entry under local anesthesia, advancement 
of 5-8F 60 cm guiding sheath over 35 hydrophilic 
wire 3cm below Saph-fem junction
• Now working under fluoroscopy guidance (C 
arm) , descending phlebography during valsalva 
maneuver realizing reflux cartography
• Introducing 5-7 Fogarti occlusive balloon catheter, 
inflating the balloon at the junction
• new occluded phlebography to adjust balloon-
sheath position  
• Smoothly injecting foam-contrast mixture to fill 
the totality of incontinent network
Procedure average time 23 minutes, 3 % sclerosing 
agent average dose is 3.5 ml (1,5 - 7)
RESULTS: Out of 47 duplex controlled cases for 
more than 1 year, 44 show complete occlusion 
of GSV, tributaries and junction till the CFV who 
keeps a normal aspect with no deformity or 
bulging thrombus, one AAV recurrence and tow 
asymptomatic segmental recanalization.
CONCLUSION: FGBSS is effective, inexpensive, 
rapid and well tolerated method, it treats GSV and 
all incontinent brunches till junction, it must be 
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PULMONARY ENDARTERECTOMY FOR CTEPH (CHRONIC THROMBOEMBOLIC 
PULMONARY HYPERTENSION)
Tankut Akay
Baskent University, Ankara, Turkey
tankutakay@gmail.com
Although the exact prevalence and annual 
incidence of Chronic Thromboembolic Pulmonary 
Hypertension (CTEPH )are
unknown, studies suggest that this condition may 
occur in approximately 4 to 5% of patients after 
an acute pulmonary embolism, making CTEPH 
one of the most common causes of precapillary 
pulmonary hypertension. However, it is likely that 
CTEPH remains significantly underdiagnosed. -In 
chronic thromboembolic pulmonary hypertension, 
thromboemboli do not undergo resolution but 
instead become highly organized and fibrotic, 
resulting in obstruction of segments of the pulmonary 
vascular tree. Progressive pulmonary hypertension 
ensues, with substantial associated morbidity and 
mortality.
Despite advances in medical therapy for some types 
of pulmonary hypertension, surgical pulmonary 
endarterectomy, also referred to as pulmonary 
thromboendarterectomy, is the mainstay of therapy 
for patients with chronic thromboembolic pulmonary 
hypertension (CTEPH). This operation leads to major 
clinical improvement and is a potential cure for a large 
majority for patients suffering from CTEPH. PTE is 
performed under cardiopulmonary bypass (CPB) and 
requires deep hypothermic circulatory arrest (DHCA) 
to complete the endarterectomy of the segmental 
and subsegmental branches of the pulmonary 
arteries. Here we tried to aim to emphasize the 
importance of this disease present our technique. 
PAD
ENDOVASCULAR MANAGEMENT OF SFA DISEASE
Sandeep Raj Pandeey 
Annapurna Hospital, Kathmandu, Nepal
sandeeprajpandey@gmail.com
Keywords: SFA, CTO, VCD, CIA, EIA
Background: SFA disease is responsible for > 
50% of PAD Cases.Vascular Access for SFA disease 
management are Antegrade CFA puncture , 
Contralateral retrograde access over the aortic 
bifurcation , Retrograde pop A access, Brachial access 
& pedal access. Endovascular management of SFA 
disease done by angioplasty , Stenting , Directional 
atherectomy ,Rotational atherectomy ,Laser 
angioplasty ,Intra-arterial radiation or Cryotherapy. 
Materials & methods:
Case 1
52 yrs M ,DM & CAD with h/o lt. femur fracture 3 yrs 
back having lt. LL claudication & great toe ischemic 
ulcer. Doppler: multiple stenotic lesions with CTO 
in distal lt SFA. Cath: Left SFA POBA done which 
increased pedal flow & healed ulcer.
Case 2
67 yr M: severe claudication(Fontiane stage ll 
B;Rutherfors category 3) of Rt leg .Pedal pulses absent. 
CTA: aorto-iliac & b/l lower limbs atherosclerotic 
disease(TASC A lesion). Small outpouching in Rt 
CIA(9x4mm). Rt EIA:75% stenosis with 23 mm in 
length. Rt distal SFA: long segment 30 cm focal CTO 
with distal reformation of pop A via collaterals. ATA 
& PTA: normal course & caliber. Rt SFA angioplasty 
with 0.035 & 0.014 hi-torque 300 cm wires & 5 mm 
x 150 mm x 135 cm balloons via 35 ll pta catheters 
percut via lt CFA access. During ballooning in distal 
SFA,there was dissection which was treated with 
stent (Absolute pro ll,Peripheral self expanding stent 
PAD
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system, 5 x 150 mm, 135 cm). EIA angioplasty with 
complete CIA & EIA stenting by Abbott vascular, 
Absolute pro lI, 8 x 120 mm, 135 cm stent was done.
Case 3
A 72 yrs old gentleman presented with disabling 
Claudication left leg.
H/O CABG, Bilateral SFA Stenting, DM, HTN. LOCAL 
EXAMINATION Left Leg: Popliteal and Pedal pulses 
were absent. No wound/Ulcer
Colour Doppler: Stenosis at distal end of previously 
placed left SFA stent. Short segment 100 % occlusion 
at distal SFA (adductor canal) with reformation of 
popliteal artery. Monophasic flows in infrapopliteal 
vessels Access -Right femoral retrograde.6 F crossover 
sheath.
Selective Femoral angiogram: Previously placed 
left SFA stent was patent with >50 % edge stenosis 
at distal end of Stent. There was 100 % short segment 
(< 5cm) occlusion of distal SFA (adductor canal) with 
reformation of popliteal artery.
Using routine 0.035 glide wire & 4 F catheter 
combination the CTO was crossed. Pre-dilatation was 
done with compliant 5mm PTA balloon dilatation 
catheter. This was followed by inflation DEB 
(Medtronic, IN.PACT Amphirion drug-eluting balloon, 
6 mm x 60 mm) at the region of CTO and previously 
stented segment respectively. Inflation time of DEB 
was 3 min. Access site homeostasis achieved using 
Proglide VCD. There was satisfactory opening up of 
the stent edge stenosis & satisfactory recanalization 
of the distal SFA occlusion with non-flow limiting 
small dissection flap and good distal run off.
Results: Case 1 got ulcer healed post angioplasty & 
all 3 cases improved of claudication well following 
angioplasty or stenting.
Conclusion: Angioplasty works best for short SFA 
stenoses or occlusions. However, angioplasty with 
stenting is likely superior initial Rx for intermediate 
and long length lesions.
PAD
PTA PROCEDURES AFTER PREVIOUS VASCULAR SURGERY
Tomislav Šipić, Krešimir Štambuk, Andrija Škopljanac-Mačina
Magdalena – Clinic for Cardiovascular Diseases, Krapinske Toplice, Croatia
tomislavsipic2@gmail.com
Keywords: critic limb ischemia, vascular surgery, PTA 
procedure, vascular team
Backgroud: More than last 30 years we are witnessing 
the epidemia of cardiovascular diseases including 
peripheral vascular disease. The treatment of 
peripheral vascular disease could be conservative, 
endovascular and surgical. These days we are facing 
with lot of patients that are previously operated and 
now having new ischemia. This happens beacause 
the atherosclerosis is chronical progressive disease 
that attacks many vessels. With time passing by, many 
new problems are created (lack of vascular approach, 
lot of comorbidities, no possibility of surgical re-do, 
advanced age etc). 
Methods and patiets: There are no specific guidelines 
how to treat those patients, so they are candidates 
for multidisciplinar approach,, so called vascular 
team. It includes: vascular surgeon, interventional 
cardiologist/radiologist, anaesthesiologist and some 
times cardiac surgeon. Vascular team is here to 
collaborate and decide how to treat patients in their 
best interest. 
Results: This presentation shows some clinical cases 
with critical limb ischemia with previous vascular 
surgery succesfully treated with PTA procedure.
Conclusion: endovascular approach may be an 
excellent solution for treatment vascular patients 
with previous vascular surgery
PAD
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SUPERFICIAL FEMORAL AND POPLITEAL ARTERIES LONG OCCLUSIONS: 
ANOTHER WAY OF REVASCULARIZATION
Leonid Magnitskiy1, Maxim Kuznetsov2, Sergey Sapelkin2
1Pirogov city hospital №1, Moscow, Russia
2Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia
fosgin@mail.ru
Keywords: popliteal artery, bypass surgery, 
endarterectomy, occlusion
Objective: No consensus in treatment of superficial 
femoral and popliteal arteries long occlusion causing 
limb ischemia is present nowadays. Femoropopliteal 
bypass below-knee position has significant 
disadvantages: small diameter of popliteal artery 
doesn’t always corresponds with blood flow from 
femoral artery due to high peripheral vascular 
resistance, while collateral arteries surrounding knee 
joint are excluded from circulation. We hypothesized 
that consecutive endarterectomy using direct 
posterior approach in prone position and above knee 
femoropopliteal bypass (E+FemPop bypass) in supine 
position (Patent RF 2601698) would present a better 
outcome than distal femoro-popliteal bypass. Long-
term results of retrospective study will be presented.
Methods: 66 patients were included: 34 underwent 
E+FemPop bypass (I group), and 32 – distal 
femoropopliteal bypass (II group). Indications for 
surgery were claudication in 20, rest pain in 24 and 
tissue loss in 22. All patients had TASC D lesions 
affecting superficial femoral artery and P1, P2 or all 
segments of popliteal artery. At least 1 crural artery 
was patent from origin to at least 8 cm distally.
Results: Primary patency after 74 months of follow-
up was 42,05% for E+FemPop bypass and 15,92% 
for distal bypass (p = 0,021, log-rank test), and 
secondary patency was 57,8% and 22,59% (p = 
0,017), respectively. Limb salvage after 74 months 
was 66,91% after E+FemPop bypass and 59,07% 
after femoropopliteal bypass below knee surgery 
(p = 0,33): 10 amputations in I group (40% major), 9 
amputations in II group (100% major). Cumulative 
primary, secondary patency and limb salvage after 
133 months in I group were 37,85%, 52,95% and 
30,81% respectively.
Conclusions: E+FemPop bypass is a good option for 
surgical repair in superficial femoral and popliteal 
arteries occlusions, with better primary and 
secondary patency rates then distal bypass surgery. 
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CRITICAL LEG ISCHEMIA, THE ULTIMATE DEBATE, OPEN VERSUS 
ENDOVASCULAR
Tankut Akay
Baskent University, Ankara, Turkey
tankutakay@gmail.com
Introduction: Patients with critical leg ischemia (CLI) 
demand a disproportionately large commitment 
both in medical effort and economically and 
represent the major workload for vascular surgical 
units. endovascular revascularization has become 
an alternative to surgery as a method for the salvage 
of critically ischemic legs. We tried to shared our 
comparison between two methods for CLI.
Methods: We retrospectively analyzed uour patients 
with critical leg ischemia (CLI). Between 2008 
and 2017, 287 patients were treated wtih CLI, 216 
underwent revascularization. 33 underwent primary 
amputation and 38 with medciical treatment and 
woundcare. 114 had Diabetes Mellitus, 54 had 
Chronic renal failure and 21 had both. We compared 
surgical and endovascular interventions in terms of 
mortality, and amputation . Demographic data is 
summarized in table 1. 
Results: There was no difference in hospitalization 
(24 - 71 days). Follow up period 34.3 ± 5 months. 
Hospital mortality in 3 patients in open surgery group 
and 2 patients in endovascular group. Late mortality 
was 7 patients in open surgery group and 9 patients 
in endovascular group. Amputation free survival 
in open surgery group in 1, 2 and 3.rd years 82 %, 
78 % and 75 %. Amputation free survival in open 
surgery group in 1, 2 and 3rd years 85 %, 79 % ve 68 % 
Secondary intervention is higher in endovascular 
group (12 % vs 5.9 %). 
Conclusion: Each treatment modality provides 
solutions for CLI. Custom made solutions is essential 
for each cases. Using new classifications are helpful in 
decision making.
     OPERATION   ENDOVASCULAR
 CRF    23 Patients (22.7 %)  31 Patients (26.9 %)
 DM     63 Patients (62.3 %)  51 Patients (44.3 %) 
 KBY +DM    8 Patients (7.9 %)  13 Patients (11.3 %)
 AGE    67.4 ± 11.2   65.1 ± 9.8
 greft ve flap    18 Patients (17.8 %)   22 Patients (19.1 %)
 HBO 1    14 Patients (13.8 %)   17 Patients (14.7 %)
 EGF    9 Patients (8.9 %)  13 Patients (11.3 %)
 coronary arter disease   17 Patients (16.8 %)  24 Patients (20.8 %)
 Table-1 demographic data of the patients 
PAD
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PEDAL ARCH IN DIABETIC PATIENTS
Nicola Troisi
Department of Surgery, Vascular and Endovascular Surgery Unit, San Giovanni di Dio Hospital, Florence, Italy
troisimd@gmail.com
Aim: To retrospectively evaluate the impact of pedal 
arch quality on tissue loss and time to healing in 
diabetic patients with foot wounds undergoing 
infrainguinal endovascular revascularization.
Materials and methods: Between January 2014 and 
June 2015, 137 consecutive diabetic patients with 
foot wounds underwent infrainguinal endovascular 
revascularization (femoro-popliteal or below-the-
knee, arteries). Postprocedural angiography of 
the foot was used to divide the patients into the 
following three groups according to the pedal arch 
status: complete pedal arch (CPA), incomplete pedal 
arch (IPA), and absent pedal arch (APA). Time to 
healing and estimated 1-year outcomes in terms of 
freedom from minor amputation, limb salvage, and 
survival were evaluated and compared among the 
three groups.
Results: Postprocedural angiography showed the 
presence of a CPA in 42 patients (30.7%), IPA in 60 
patients (43.8%), and APA in 35 patients (25.5%). 
Healing within 3 months from the procedure was 
achieved in 21 patients with CPA (50%), 17 patients 
with IPA (28.3%), and in 7 patients with APA (20%) 
(P=.01). There was a significant difference in terms 
of 1-year freedom from minor amputation among 
the three groups (CPA 84.1% vs. IPA 82.4% vs. APA 
48.9%, P=.001). Estimated 1-year limb salvage was 
significantly better in patients with CPA (CPA 100% vs. 
IPA 93.8% vs. APA 70.1%, P <.001). Estimated 1-year 
survival was significantly better in patients with CPA 
(CPA 90% vs. IPA 80.8% vs. APA 62.7%, P= .004).
Conclusions: Pedal arch status has a positive impact 
on time to healing, limb salvage, and survival in 
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CARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 
COMPARED WITH CONTINUED SMOKING
Reuven Zimlichman, Emilija Veljković, Gizelle Baker, Christelle Haziza, Julia Hoeng, Nikolai Ivanov,   
Frank Luedicke, Serge Maeder, Manuel Peitsch, Patrick Picavet, Blaine Phillips, Carine Poussin,  
Patrick Vanscheeuwijck
PMI R&D, Philip Morris Products S.
A., Quai Jeanrenaud 5, CH-2000 Neuchâtel, Switzerland
zimlich@bezeqint.net
Cigarette smoking is causally linked to the 
development of cardiovascular diseases. For many 
decades, reducing tobacco harm has been focused 
on preventing smoking initiation and promoting 
smoking cessation. In recent years, the tobacco 
harm reduction approach has emerged, which 
focuses on providing smokers who do not quit with 
a new generation of smoke-free products that have 
the potential to be substantially less harmful than 
cigarettes. The Tobacco Heating System (THS) 2.2 is 
a novel tobacco product that heats tobacco instead 
of burning it, never allowing the temperature to 
exceed 3500C, thereby preventing combustion and 
producing substantially lower number and levels of 
toxicants than CS. 
Our assessment program includes in vitro/in vivo 
toxicology testing and randomized, controlled 
clinical studies. 
The results of the THS translational assessment 
program demonstrated that cardiovascular toxicants 
are reduced by more than 92% in THS aerosol versus 
smoke and that THS aerosol contains no solid carbon-
based nanoparticles. The effects of THS aerosol on 
adhesion of monocytic cells to human coronary 
endothelial cells in vitro are significantly reduced. 
Switching to THS halted the progression of smoke-
induced atherosclerotic changes in ApoE-/- mice in 
in vivo studies. 
Clinical risk endpoints (CRE) linked to the development 
of smoking-related diseases were analyzed following 
a 6-month randomized, controlled clinical study with 
THS, which demonstrated consistent improvement in 
CREs in different pathophysiologic pathways leading 
to atherosclerosis. 
The evidence available to date indicates that 
switching to THS has the potential to reduce the risk 
of smoking-related diseases, such as cardiovascular 
diseases.
NOACS – PHILIP MORRIS SPONSORED LECTURE
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INFLAMMATION AND VENOUS THROMBOSIS: WHAT IS THE CONNECTION?
Pavel Poredoš 
The University of Texas Health Science Center at Houston, Department of Advanced Cardiopulmonary Therapies and 
Transplantation, Houston, Texas, USA
pavel.poredos@kclj.si
During the last decade, the role of inflammation 
in the etiopathogenesis of arterial thrombosis has 
been elucidated. However, little is known about 
the relationship between inflammation and venous 
thrombosis. Recently, inflammation has been 
accepted as a possible mechanism through which 
different risk factors trigger thrombus formation 
in veins. The data indicate that inflammation of the 
vessel wall initiates thrombus formation in an intact 
vein and that inflammation and coagulation systems 
are coupled by a common activation pathway. 
The first event in thrombus formation is most 
probably activation of endothelial cells, platelets 
and leucocytes, with initiation of inflammation 
and formation of microparticles that trigger the 
coagulation system through the induction of 
a tissue factor. Therefore, the key event in the 
initiation of venous thrombus formation is most 
probably vein wall inflammation. However, expected 
relationship between inflammatory markers as 
indicators of inflammatory process and clinical 
venous thromboembolism (VTE) has not yet been 
elucidated. C-reactive protein does not appear to 
be useful in predicting future venous thrombosis or 
to be useful in the diagnosis of VTE. Recently, it was 
demonstrated that probable association between 
VTE and several other markers of inflammation such 
as: interleukin (IL)-6, IL-8 and tumor necrosis factor-a 
exists. While these markers of inflammation were 
studied during or after acute venous thrombosis, 
further prospective studies are needed to determine 
the predictive value of inflammatory markers for VTE. 
The identification and elucidation of inflammatory 
markers relevant to venous thrombosis could 
provide targets for future therapy. That inflammation 
is the basic etiopathogenetic process of VTE is also 
supported by the relation of some risk factors to both 
arterial and venous thrombosis: age, increased body 
mass index, hypercholesterolemia, hypertension, 
lupus anticoagulant and hyperhomocysteinemia. 
A relation was also found between preclinical and 
clinical atherosclerotic disease and VTE. Also in line 
with these arguments are the preventive effects 
of aspirin and statins in both arterial and venous 
disease.
NOACS
NOACs IN VENOUS THROMBOEMBOLISM AND PERIPHERAL  
ARTERIAL DISEASE
Ingrid Prkačin1,2
1School of Medicine, University of Zagreb, Zagreb, Croatia
2Clinical Hospital Merkur, Zagreb, Croatia
ingrid.prkacin@gmail.com
Keywords: NOACS, VTE, PAD
Several new or direct oral anticoaulants (NOACs), 
e.g. direct thrombin inhibitor (dabigatran) and 
direct factor Xa inhibitors (rivaroksaban, apiksaban) 
became over the last decade alternatives to old 
anticoagulant(VKA). NOACs offer rapid onset and 
offset of action, predictable anticoagulant effects 
and fewer drug and food interactions without the 
need for frequent monitoring. In addition, all the 
NOACs undergo kidney clearance to varying degrees.
Venous thromboembolism (VTE) is categorised as deep 
venous thrombosis (DVT) and pulmonary embolism 
(PE). Anticoagulant therapy is recommended in 
patients with DVT or haemodynamically stable non-
high-risk PE. Combination therapy – heparin or other 
parenteral anticoagulation followed by an oral VKA – 
NOACS
44
Acta Chirurgica Croatica Abstracts of Oral presentations
is a traditional approach. However, since recently the 
NOACs have provided an alternative to VKAs and also 
offer the option of a single oral drug from the start of 
therapy.
Persistent oral anticoagulant therapy in combination 
with antiplatelet therapy (for at least 1 month after 
percutaneous peripheral vascular revascularization) 
is indicated in patients with peripheral arterial disease 
(PAD) and atrial fibrillation with CHA2DS2-VASc ≥ 2 or 
in patients with mechanical valve.
The incidence of amputations in patients with PAD 
is associated with control of systolic blood pressure, 
which is very often lacking. Angiotensin-converting 
enzyme (ACE-I) inhibitors and angiotensin receptor 
antagonists (ARBs) can significantly reduce 
cardiovascular risk in patients with PAD.
The future of treatment for peripheral arterial disease 
is the administration of antiplatelet monotherapy 
with vascular dose of NOACs.
NOACS
CAN WE REDUCE THE INCIDENCE OF THE POST-THROMBOTIC SYNDROME?
Pier Luigi Antignani
President elect of International Union of Angiology
Director, Vascular Center, Nuova Villa Claudia, Rome, Italy
antignanipl@gmail.com
The post thrombotic syndrome (PTS) is the major 
chronic sequel of deep vein thrombosis (DVT) of 
the leg and it is a major socio-economic challenge. 
In addition to systematic prophylaxis of DVT in 
hospitalized patients, effective management of DVT 
is important to reduce the incidence of PTS.
Correct diagnostic strategy and optimal 
anticoagulation are important to prevent the 
recurrent DVT which is the major risk factor for PTS.
Regarding the DOACs, extended anticoagulation 
may be promising for reducing the risk of PTS in 
comparison with standard anticoagulant therapy. 
Our data suggeted that they have a strong action on 
endogenous fibrinolysis, reducing early not only the 
recent thrombus but also the organized thrombus 
with, as result, a complete recanalization of affected 
veins and consequent reduction of incidence of PTS, 
saving the valves structure.
Aim of our clinical-instrumental observational 
research is to observe the anticoagulant effect of 
Rivaroxaban in patients with recent and previous 
VTE and in particular if the DOACs have a fibrinolytic 
effects on new and older thrombus.
We studied two groups of patients:
The first group: 27 subjects, age 50-70 years, with 
previous popliteal-femoral DVT.
• Complete femoral recanalization and partial 
popliteal recanalization (30%).
• Normal creatinine clearence and liver function.
The second group: 19 subjects, age 70-85 years, 11 
males and 8 females.
• Parzial recanalization of popliteal vein (30%)
• Recent femoral re-thrombosis in previous 
popliteo-femoral DVT (about 3 years ago).
• Normal creatinine clearance and liver function.
The patients followed the AVKs therapy but modified 
the treatment for no compliance to dicumarols and 
starts with DOACs (rivaroxaban 15 mg BID for three 
weeks, then 20 mg die). 
All patients were submitted to clinical and echo 
duplex evaluations every week for 30 days.
In the first group we observed the complete 
racanalization of popliteal thrombosis after 30 days.
In the second group we observed the complete 
recanalization of recent femoral thrombosis after 14 
days and the complete recanalization of old popliteal 
thrombosis after 30 days.
No adverse events were observed.
These results show the fibrinolytic activity of DOACs 
also in patients with old thrombosis with partial 
recanalization. This action is useful to reduce the 
posthrombotic syndrome preserving the integrity of 
valves.
The introduction of non-vitamin K antagonist oral 
anticoagulants (DOACs) has fundamentally changed 
clinical practice in the use of oral and parenteral 
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anticoagulation therapy in the treatment of venous 
thromboembolism.
Some laboratory tools for determining the rate 
of thrombus formation and fibrinolysis in whole 
blood and plasma include techniques such as the 
thrombelastograph (TEG) and an assay performed in 
a 96-well microtitre plate (MPA). As reported by Y.C. 
Lau (J Thromb Thrombolysis (2016;42:535–544) the 
rate of clot dissolution is more rapid in rivaroxaban 
patients. 
The TEG and MPA identify differences in 
thrombogenesis and fibrinolysis in different 
NOACs with major action in rivaroxaban patients. 
Rivaroxaban had the greatest influence of slowing 
thrombogenesis, giving a result (69 % inhibition) 
close to that of warfarin (65 % inhibition). 
This result was confirmed in the EINSTEIN PE study 
(van Es J et al, J Thromb Haemost 2013;11:679–685) 
in which was observed the early clot regression 
following acute PE (88 % of clot complete of partial 
resolution after 21 days of treatment). 
Better allocation of therapy based on an uniform 
diagnostic srtategy and risk stratification, supported 
by risk prediction models, might also improve the 
outcome of existing therapies.
More researchs should be undertaken to traslate 
pathophysiologic mechanisms of thrombus 
resolution and PTS development, into identification 
of PTS specific targets for pharmacotherapeutic 
intervention.
The correct treatment of DVT with DOACs represent 
the good and the diverse to counteract the dangerous 
network among hemodynamic, inflammatory and 
proteolytic processes occurring from the early 
stages of symptomatic varicose veins to severe 
steps of ulcers including the post-thrombotic 
patients, stigmatizing the fundamental role of the 
biomolecular mechanisms of endothelium in the 
management of vascular diseases
NOACS
THROMBOLYTIC TREATMENT OF PULMONARY EMBOLISM
Matija Kozak
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Pulmonary embolism (PE) is a disease with several 
different clinical presentations. The patients could be 
at low, medium or high risk for serious consequences. 
Patients with high risk PE are in schock or are 
haemodynamicly unstable and these patients should 
be treated with thrombolysis, which could quickly, 
by disolving the occlusions, diminishes the right 
ventricle overload, which is the main risk for dying 
and serious consequences. Such treatment markedly 
improves their outcome. In patients with increased 
risk of bleeding like patients with previous stroke 
or recent cerebral injury, recent gastrointestinal 
bleeding or increased bleeding risk there is absolute 
contraindication for thrombolysis. Bleeding especially 
intracranial, which could be expected in about 1 
% of treated patents, is the main serious adverse 
event of thrombolysis. There are several therapeutic 
regimes of thrombolysis. The most suggested and 
approved is treatment with recombinant tissue 
plasminogen activator 100 mg i.v. in two hours. 
The bleeding during thrombolysis is also the main 
concern, when patients with intermediate high 
risk PE are concerned. In these pateints it has been 
shown that thrombolysis is effective in prevention 
of haemodynamic instability or dying due to PE, 
but it is also accompanied by serious bleedings and 
there is no effect on longterm outcome although 
thrombolysis quickly improves clinical status in the 
acute state. So, using thrombolysis in a conventional 
way in such patients is questionable. There are several 
other regimes of thrombolysis like catheter directed 
or catheter directed with some mechanical support, 
but their role is still debatable.
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BLEEDING AS A MAJOR CAUSE OF EMERGENCY ATTENDANCE IN PATIENTS 
ON DIFFERENT ORAL ANTICOAGULANTS
Petra Pervan1, T Svagusa2, I Cvjetko3, M Mioc Pezic4, G Cavric3, I Prkacin3
1Health Center Zagreb-Centre, Zagreb, Croatia
2Clinical Hospital Dubrava, Zagreb, Croatia
3University Hospital Merkur, Zagreb, Croatia
4General Hospital Vinkovci, Vinkovci, Croatia
ppervan21@gmail.com
Keywords: Anticoagulant therapy, bleeding, 
emergency department, chronic kidney disease
Anticoagulant therapy is increasingly used in world, to 
prevent and treat thromboembolic incidents, which 
can lead to fatal outcome or lower quality of life.
The main causes are an aging population and many 
conditions that require this type of therapy suach 
as pulmonary embolism, deep vein thrombosis and 
atrial fibrillation.
Since bleeding occurs in patients using warfarin, as 
well in patients using DOACs, the aim of this study 
was to determine whether there is a difference in the 
frequency of bleeding, as a major cause of emergency 
attendance, between these two groups.
Study included 48 patients examined in Emergency 
Unit in Clinical Hospital Merkur in period of 3 
months, who had been using anticoagulant therapy. 
In patients who had chronic kidney disease (stage 
2-4) drug doses were adjusted according to GFR. 22 
patients in Gropu A used warfarin, of which 8 were 
men, and 26 patient in group B used direct oral 
anticoagulants, 6 of them were men. The median age 
in group A was 80.77 years, while in group B was 81.77 
years. There were no differences in comorbidities 
between those 2 groups.
In group A, main cause of emergency attendance in 14 
(64%) patients, was bleeding, mostly from digestive 
tract, while in group B, bleeding was the main cause 
in 8 (31%) patients. Chi square test was used to test 
the difference in the frequency of bleeding as a cause 
of emergency attendance and a value was χ2 = 8.777 
which gives p < 0.01.
Results suggest that in patients who used direct oral 
anticoagulants as anticoagulant therapy, adapted to 
the renal function, were significantly less bleeding, 
than in those who used warfarin. This study confirms 
the safety of DOACs over warfarin in the reduction 
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ENDOVASCULAR TRETAMENT OF CHRONIC VENOUS DISEASE (FOAM, LASER, 
RF AND GLUE)
Sorin Olariu, Sonia Rațiu, Andrei Părău, Sergiu Matei, Andra Olariu
University of Medicine and Pharmacy Victor Babeș Timișoara, Romania, Surgical Clinic I
olariu.sorin@umft.ro
Keywords: AVLA, VENEFIT, VENASEAL, 
CRYOSTRIPPING, MOCA
The purpose of the presentation is to evaluate the 
effectiveness of the various endovascular methods 
used in the treatment of chronic venous disease.
Material and methods: We have used the literature and 
the recommendations of the latest European guide 
on the large and small saphenous truncal ablation, 
along with personal experience with cryostripping. 
Several technical elements of the chronic venous 
disease cure are presented: endovenous laser (EVLA), 
radiofrequency (Venefit), mechanochemical method 
(MOCA), venaseal, ablation by cryostripping.
Results, discussions: The effectiveness of the various 
techniques presented is analyzed based on studies 
published in the literature.The occlusion rate in 
endovenous laser ablation was early 95 - 100 %, at 5 
years from 65 % to 95 %. In the case of radiofrequency 
ablation the results were early 90 - 100 %, 92 - 94,2 % at 
5 years. The glue technique was early successful in 93 - 
99 % of cases and 94,4 % at 3 years. Mechanochemical 
ablation has an early occlusion rate in 87 - 99 % cases 
and 87 % at 3 years. The cryostripping method was 
in 98 - 100 % effective in early period and in 96 - 98 
% at 5 years. The endovenous foam had the weakest 
results reported:early occlusion in 45 - 96 % cases 
and 23 - 68,5 % at 5 years.
Conclusions: Reflux in the internal and external 
saphenous vein territory has endovenous laser, 
radiofrequency and cryostripping the method of 
choice. Surgery and sclerotherapy are on the second 
plane. Mechanochemical ablation and glue are 
applicable but require further studies on results. 
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PELVIC CONGESTION SYNDROME UNKNOWN ASPECTS
Louay Altarazi1,2 , A Hssan2 , I Kabani2
1Damascus University, Syria
2Varicose veins & vascular clinic, Salhieh Tower, Damascus, Syria
Keywords: Pelvic congestion, Varicose veins, Pelvic 
veins anomalies
Objectives: Pelvic congestion syndrome PCS may 
be the most controversial vascular pathology, Syrian 
prevalence national study in 2005 screened about 
5000 young women from different region showed 
proven PCS in about 16 % in urban cities and 24% 
in countryside and Sahara regions due multiple 
pregnancies.
Since 2001 our team is taking in charge hundreds 
of cases annually with the advantage that the same 
doctor is interviewing patient, doing ultrasounds, 
supervising the file and treatment decision and 
executing endovascular sclerosis-embolization so 
we have classified a lot of new clinical and anatomic 
patterns.
The aim of this presentation is to expose some 
overlooked and unknown aspects of PCS that we 
have encountered so we have changed our protocols 
as we are looking for them in every new patient. 
Methods: PCS has extraordinary manifestation 
variability, some manifestation are well-known 
(lower dorsal and abdominal pain, dyspareunia-
dysmenorrhea-dysuria, heavy legs and atypical 
or recurent varicose veins) others are less known 
(hemorrhoids, tenesmus, hematuria and left flank 
pain ). 
We will try to elucidate ,expos , share and discus 
our experience concerning other unknown 
manifestations:
• recanalized or repermialized sciatic vein
• anatomic anomalies 
• male PCS
• ovarian vein urinary compression syndrome
• ovarian vein thrombosis
• huge veins
Results: Between 2001-2019 we have taken in charge 
about 4800 proven PCS files and we have treated 
more than 860 case by endovascular approach so we 
begin to distinguish those special PCS patterns.    
Conclusion: With its three floor (ovarian, pelvic 
and lower limbs) manifestations PCS doesn’t stop 
surprising us, every case is special one, anatomic or 
clinical pattern deserves further studies and better 
definition and classification.  
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CHRONIC VENOUS OBSTRUCTION: WHAT IS IT AND HOW  
CAN WE MEASURE IT? 
Christopher R Lattimer
Josef Pflug Vascular Laboratory, Ealing Hospital & Imperial College, West London Vascular and Interventional Centre, 
London, UK
c.lattimer09@imperial.ac.uk
Chronic venous obstruction (CVO) is poorly 
understood. It is caused usually by the aftermath of 
a deep vein thrombosis (DVT). Here, the pathology 
of the lesion is post-thrombotic fibrosis (PTF). This 
results in luminal obstruction, valve scarring and 
vein wall stiffness. Clinically, this is manifest as the 
post thrombotic syndrome (PTS). In some cases, 
the lesion is non-thrombotic occurring typically 
in the iliac veins. The classification of these lesions 
“adhesions” were described by the anatomist Playfair 
McMurrich in 1906 with a frequency of 32.7% in the 
normal population. Over half a century later, May and 
Thurner (1957) described a compression syndrome 
where the left common iliac vein is squashed as 
it passes between the right common iliac artery 
and the spine. This is a common CT finding where 
a >50% reduction in diameter of the vein occurs in 
25% of the asymptomatic population. Since many 
scans are performed supine it remains debatable 
whether the narrowed vein demonstrated represents 
a true stenosis, venous collapse or merely a C-shaped 
indentation of no haemodynamic significance. If 
CVO is defined correctly as an impediment to venous 
drainage rather than a lesion, then the aetiology 
broadens. Obesity, tall stature, raised intra-abdominal 
pressure and right heart failure enter the picture. 
Furthermore, reflux disease, luminal shape, tortuosity 
and reduced venous tone are included. The inter-
relationships between the lesion, a compression 
and impeded drainage make the assessment of CVO 
complex and problematic. Furthermore, the failings 
of an adequate clinical assessment questionnaire, like 
the Villalta scale, and the injudicious use of diameter 
measurements, hamper decision making when they 
are used to interpret randomized controlled trials. 
The venous drainage index (VDI) of air-
plethysmography measures the rate of decongestion 
of the calf (mL/s) in response to leg elevation. The 
new user friendly interface now positions the test 
for screening everyone in the outpatient setting 
prior to specialist review. Patients with a significant 
venous impediment to drainage have a (i) reduced 
VDI, (ii) an increase in the time taken to drain and an 
(iii) undrained volume, termed the drainage reserve 
volume (DRV). Furthermore, (iv) the drainage tracing 
is a curve (hydrostatic drainage) instead of a normal 
straight line (waterfall drainage). All 4 parameters 
should improve if the intervention to relieve the CVO 
was the correct decision.
NEWS IN PHLEBOLOGY
ENDOVENOUS HEAT INDUCED THROMBOSIS
Sandeep Raj Pandeey
Annapurna Hospital , Kathmandu, Nepal
sandeeprajpandey@gmail.com
Keywords: EHIT, DVT, SFJ, SPJ
Background: EHIT is propagation of a thrombus 
from a SV into a DV post EVTA.Generally considered 
clinically insignificant if the thrombus does not 
propagate to the DV system. EVTA of the saphenous 
vein has become one of the preferred Rx for treating 
saphenous vein reflux resulting in symptomatic 
lower extremity CVI or VV. Initial reports had a low 
incidence of postop thrombosis of the DV adjacent 
to the treated GSV or SSV. Later clinical experience 
suggested that the actual incidence of this event is 
higher & it was subsequently termed EHIT. EHIT is 
classified into EHIT 1- EHIT 4.
Materials & methods: >400 patients treated with 
EVTA at my center from Jan 2015 - Dec 2017. 
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Results: Have encountered 55 EHIT 1,no any Rx fr 
them.5 patients with EHIT 2 were Rx with LMWH for 
1-2 weeks depending upon when the patient was 
reclassified by USG to Class 1. 1 patient in class 3 
treated by LMWH fr a week & warfarin for 1 month.
After a month kept her on aspirin fr another one 
month. There were no patients in class 4. 
Conclusion: EHIT behave differently than a 
spontaneous DVT, displaying USG chronicity at a 
much earlier time. Close duplex USG observation of 
EHIT 1 without pharmacologic Rx. Treatment of EHIT 
2 with LMWH until the EHIT can be reclassified to 
EHIT 1 by duplex USG. EHIT 3 or 4 should be treated 
according to the suggested guidelines for DVT.Better 
understanding of the clinical significance of EHIT in 
proximity & beyond the SFJ/SPJ with EVTA continuous 
popularity should be continued with further studies.
This will ultimately allow us to make more definitive 
recommendations regarding treatment options.
NEWS IN PHLEBOLOGY
CANCER RELATED DVT – WHAT IS NEW IN THE TREATMENT?
Larisa Chernukha
Vascular Surgery Department, A. A. Shalimov National Institute of Surgery and Transplantology National Academy of 
Medical Science of Ukraine, Kiev, Ukraine
vasc.phlebo@gmail.com
Risk of venous thromboembolism (VTE) vary from 
cancer diagnosis to its treatment. The annual 
incidence rate of the cancer related DVT or cancer-
associated thrombosis (САТ) is from 0,5 to 20 % and 
it depends on type and location of cancer, metastasis 
status, cancer treatment (surgery or chemotherapy), 
usage of central venous catheter, hospitalization and 
patient’s risk factors.
The treatment and prevention choice of cancer 
related DVT is very important to prevent not only 
thrombosis and its recurrence, but also not cause 
bleeding, especially in patients with active cancer. 
Thrombosis that can recur has noticed in ACCP 2016. 
Their cause may be cancer - unprovoked thrombosis 
(30% recurrence at 5 years) and CAT (15 % annualized 
risk of recurrence). In the treatment of CAT, LMWH is 
preferred over VKA or NOAC therapy. When recurrence 
of VTE happens after index event, it is need the 
confirmation of VTE recurrence and an assessment 
of the anticoagulation adequate, as well as the 
consideration of oncological status. If recurrence of 
VTE occurs on VKA or NOAC it is recommended to 
switch to LMWH for at least 1 month. If VTE recurrence 
occurs on LMWH it is recommended to increase 
the LMWH dose by one-fourth or one-third. The 
recommended duration of the anticoagulant therapy 
is more than 3 months (extended) with mandatory 
categorization of the risk of bleeding.
Since their appearance in the early 2000s, NOAC (later 
on DOAC – dabigatran is direct thrombin inhibitor 
and apixaban, edoxaban, rivaroxaban are inhibitors 
of activated Xa factor) quickly replaced all traditional 
anticoagulants in treatment of VTE regarding its easy 
administration and minimal requirements for their 
monitoring. Still, DOAC usage in cases of CAT was 
limited due to lack of evidence. 
Until recently all data was received from subgroup 
analysis of randomized clinical trials in patients 
with САТ (RE-COVER I, RE-COVER II, EINSTEIN-DVT, 
EINSTEIN-PE, AMPLIFY, Hokusai VTE). In these trials, 
a small number of patients with active cancer was 
included. VKA, not LMWH, was as a compared 
medicine, and appeared to be inferior to LMWH 
in terms of CAT treatment, risk of recurrence and 
bleeding rate. NOACs have shown a non-significant 
decrease of VTE recurrence and less major or clinically 
relevant bleeding rate compared to VKA. However, 
cancer patients in these trials were healthier (and had 
a lower mortality than patients in CLOT study. 
In Hokusai VTE-Cancer, Select-D, ADAM VTE trials 
patients with active cancer were enrolled aligning to 
a new definition of «active cancer».
In the Hokusai VTE-Cancer study, the recurrence 
rate of VTE was non-significant lower in patients 
that received a combination of edoxaban with 
LMWH than on dalteparin only. The incidence of 
major bleeding was significantly higher in edoxaban 
with LMWH group. The mortality rate was not 
substantially different between groups and most of 
deaths was caused by cancer. The number of deaths 
associated with VTE or bleeding was too small to 
make comparison between groups.
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In Select-D study rivaroxaban was associated with a 
lower rate of venous thromboembolism recurrence 
compared to dalteparin at 6 months. The rate of major 
bleeding was numerically higher in the rivaroxaban 
arm but with a similar rate of fatal bleeding. Overall 
survival was also similar between treatment arms. 
In these trials was also noticed that patients with 
gastrointestinal or genitourinary cancer were at 
high risk of major bleeding associated with DOAC 
treatment. 
Results on the ADAM VTE trial showed with very low 
bleeding and venous thrombosis recurrence rates 
compared to dalteparin, but the data have not been 
included in guidelines yet.
ESC2017, ESMO2017, NCCN2018, ISTH 2018, 
Canadian Expert Consensus 2018 ASCO2019, 
ESC2019 recommend LMWH as choice of treatment 
for patients with CAT within 6 months and more. 
Only edoxaban and rivaroxaban are recommended 
by for cancer patients with acute VTE, low risk 
of bleeding and no drug-drug interactions with 
current systematic therapy (results on the ADAM 
VTE trial showed with very low bleeding and venous 
thrombosis recurrence rates compared to dalteparin, 
but the data has not been included in guidelines yet). 
The treatment choice should be based on the type 
and location of the cancer, an assessment of the 
risk of bleeding, concomitant anticancer treatment, 
drug-drug interactions, patient’s preferences and life 
expectancy.
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(RE)CONSTRUCTION OF ARTERIOVENOUS FISTULA WITH CORMATRIX
Boštjan Leskovar
General Hospital Trbovlje, Slovenia
bostjan.leskovar@sb-trbovlje.si
Keywords: arteriovenous fistula, extracellular 
matrix, haemodialysis
Introduction: CorMatrix is an acellular extracellular 
matrix that acts as a biological scaffold and remodels 
into site-specific tissue. We used it for the (re)
construction of arteriovenous fistulas (AVFs).
Methods: In this prospective pilot case study, we 
used CorMatrix in 6 patients. We included patients 
who required vascular access reconstruction due 
to thrombosis of unsalvageable AVFs, patients with 
high-flow AVFs and patients with microvasculature 
in which autologous AVFs did not mature, requiring 
reconstruction with a graft. We sutured the CorMatrix 
plate into a tubular shape and then constructed end-
to-side or end-to-end arterial and end-to-end venous 
anastomoses.
Results: There were no periprocedural complications, 
CorMatrix-related infections, bleeding or limb 
swelling after the procedures. CorMatrix was 
first punctured after 8-10 weeks. In 5 patients, 
a percutaneous angioplasty due to CorMatrix 
stenosis was performed; in 1 patient, a stent was 
placed due to refractory stenosis. We observed 8 
thromboses during the observation period (4 in one 
patient). Perianastomotic stenosis of CorMatrix and 
interdialytic hypotension were the causes of the 
thrombosis in 5 patients, cephalic arch stenosis was 
the cause in 2 patients, and thromboembolism to the 
brachial artery and AVF were the causes in 1 patient. 
Thrombendarteriectomy was successful in 87.5% of 
patients, and 1 patient required AVF reconstruction. 
After a median observation period of 12.5 (range 
4–23) months, all AVFs were patent, with a median 
brachial artery flow of 1450 (range 700–1700) ml/
min.
Conclusions: AVF (re)construction with CorMatrix 
seems to be feasible and safe, with a relatively high 
incidence of neointimal hyperplasia, predominantly 
at venous anastomoses, but additional clinical and 
histological studies are needed.
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CHRONIC VENOUS INSUFFICIENCY TREATMENT: SYNERGY OF VENOACTIVE DRUGS AND SURGERY
BENEFITS OF VENOACTIVE DRUG THERAPY IN SURGICAL OR ENDOVENOUS 
TREATMENT FOR VARICOSE VEINS
Ivan Cvjetko 
University Hospital Merkur, Zagreb, Croatia
Ivan.cvjetko@yahoo.com
Introduction: Chronic venous disease affects 
significant proportion of general population Clinical 
status is commonly divided in 7 grades, raging from 
0 which means absent disease and 6 which means 
varicose veins with active leg ulcers. Therapy varies 
form conservative treatment, sclerotherapy to 
endothermal and surgical interventions. Veonactive 
drugs may be added to any treatment and at clinical 
level of the chronic vein disease.
Materials and methods: We present several studies 
including latest review and our own experience and 
case studies. There are different type of flavonoids 
that are being use solely or in combination. 
Results:  There were no side affects when micronised 
purified flavonoid fraction (MPFF) was used. 
The symptoms of the varicose vein disease have 
improved. There was excellent compliance during 
the treatment.
Conclusion: Appropriate treatment with micronised 
purified flavonoid fraction (MPFF) may help reduce 
postprocedural pain, haemorrhage and symptoms 
specific to chronic vein disease.
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PLENARY SESSION – SPECIAL LECTURE
THE USE OF A NINE STEP THERAPEUTIC LADDER IN PAD AND CLI
Nicos Angelides
University of Nicosia, Cardiovascular Surgical Unit Nicosia General Hospital, Nicosia, Cyprus
n_angelides@hotmail.com
Endoluminal treatment of severe vascular occlusive 
disease over the last years showed the existence of 
nine major steps: STEP 1, was introduced in 1977 by 
Andreas Gruentzig (recanalization of an occluded 
peripheral artery using balloon angioplasty). By the 
end of the eighties, metal stents (STEP 2) were also 
introduced in order to minimize the problem of re-
stenosis. However, metal stents generate intimal 
proliferation as well, responsible for a late re-stenosis. 
So, the use of either balloon angioplasty alone or 
in combination with metal stents may cause in 
occluded arteries a late re-stenosis at a rate shifted 
between 20% (balloon+stents) and 50% (balloon 
only). The answer to the problem was the use of 
drug eluting stents (STEP 3). These were first applied 
in the coronary arteries and later in the peripheral 
arteries as an answer to the problem of re-stenosis. 
Drug eluting balloons (STEP4) represent a novel 
option in treating occluded distal coronaries and 
distal leg arteries. Several randomized trials (i.e. 
THUNDER, PACIFIER and LEVANT 2) shed light to 
the field of drug-eluting balloons and stents. STEP 
5 of the ladder, has also emerged. This step deals 
with bio-absorbable stents made of polytactide or 
sirolimus, which resolve in about two years’ time. 
Such stents managed to remodel the occluded 
artery releasing an anti-re-stenotic drug at the 
same time. Endoluminal irradiation (STEP 6) is also 
in use as a new promising method for the occluded 
coronary arteries. However, radiation protection 
is an important parameter to consider as atypical 
malignancies have already appeared in high volume 
interventionists. Intravascular lithotripsy (STEP 7) is 
an exciting method for calcified lesions protruding in 
the arterial lumen. Lithotripsy can also decrease the 
calcium density before using a drug eluting balloons 
to remodel the occluded artery. Gene therapy (STEP 
8) is a new way to modify the endoluminal response 
and prevent re-stenosis by various techniques one 
of which is the infusion of mutant genes at the site 
of an angioplasty. Finally, stem-cell therapy alone 
or in combination with gene therapy (STEP 9 of the 
ladder), can also be applied in cases of end stage 
peripheral critical ischaemia. This kind of therapy 
is based on angiogenesis. Patients with end stage 
Buerger’s disease, by receiving multiple injections 
of volume reduced bone marrow mononuclear cells 
into the gastrocnemius muscle and the foot dorsum, 
showed six months after the injection that several 
collateral networks were developed (angiogenesis). 
A vital question is: when to attempt open surgery 
in CLI? According to consensus documents an 
open surgical procedure in patients with CLI should 
be undertaken when endovascular surgery is 
unsuccessful and there is still a 25% chance of saving 
the limb for a period of one year. However the to-
day practice, taking into account the evolution of 
technology and the expanding endovascular skill 
level, suggests an
endovascular attempt in all lesions (TASC A to D), 
prior to any surgery or amputation. 
In no option CLI a major amputation is decided when 
there is (a) no run off below the femoral artery, (b) 
when tissue loss involves the heel and (c) when 
severe rest pain exists. Below-Knee amputation, is 
the operation of choice in patients with end-stage 
CLI. The outcome of an amputation is generally poor. 
Only 4 out of 10 patients are expected to regain 
adequate mobility. Also three out of 10 patients will 
die in two years’ time as a result of atherosclerotic 
occlusions in other areas of the circulatory system.
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PAD AND RADIATION PROTECTION
SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH 
PERIPHERAL ARTERIAL DISEASE
Pavel Poredoš
The University of Texas Health Science Center at Houston, Department of Advanced Cardiopulmonary Therapies and 
Transplantation, Houston, Texas, USA
pavel.poredos@kclj.si
Atherosclerosis is considered a generalized disease. 
Similar or identical etiopathogenetic mechanisms 
and risk factors are involved in various atherosclerotic 
diseases, and the positive effects of preventive 
measures on atherogenesis in different parts of the 
arterial system were shown. However, until know, 
great emphasis has been placed on the aggressive 
pharmacological management of coronary artery 
disease (CHD), while less attention has been devoted 
to the management of peripheral arterial disease 
(PAD), despite its significant morbidity and mortality. 
Data on the efficacy of preventive measures in PAD 
patients have mostly been gained from subgroup 
analyses from studies devoted primarily to the 
management of coronary patients. These data have 
shown that treatment of risk factors for atherosclerosis 
with drugs can reduce cardiovascular events also in 
patients with PAD. The effects of some preventive 
procedures in PAD patients differ from coronary 
patients. Aspirin as a basic antiplatelet drug has been 
shown to be less effective in PAD patients than in 
coronary patients. The latest Antithrombotic Trialists’ 
Collaboration (ATC) meta-analysis demonstrates no 
benefit of aspirin in reducing cardiovascular events in 
PAD. Statins reduce cardiovascular events in all three 
of the most frequently presented cardiovascular 
diseases, including PAD to a comparable extent. 
Recent studies indicate that in PAD patients, in 
addition to a reduction in cardiovascular events, 
statins may have some hemodynamic effects. They 
prolong walking distance and improve quality of 
life. Similarly, angiotensin enzyme inhibitors are also 
effective in the prevention of cardiovascular events 
in coronary, cerebrovascular, as well as PAD patients 
and show positive effects on the walking capacity 
of patients with intermittent claudication. In PAD 
patients, the treatment of hypertension and diabetes 
also effectively prevents cardiovascular morbidity 
and mortality. As PAD patients are at a highest risk 
of cardiovascular complications, the risk factors of 
atherosclerosis should be treated intensively in this 
group of patients. Most of the preventive measures, 
including the drugs used for prevention of CHD, are 
also effective in PAD patients.
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PAOD IN HOSPITAL ADMISSIONS IN PORTUGAL - IMPACT OF 
ENDOVASCULAR TREATMENT. WHEN IS OPEN SURGERY THE FIRST OPTION? 
LESSONS FROM THE PRESENT AND THE FUTURE.
Jose Fernandes e Fernandes
Faculty of Medicine, University of Lisbon, Portugal
Lisbon Cardiovascular Institute / Hospital da Luz Torres de Lisboa, Lisbon, Portugal
jff@me.com
Peripheral arterial disease has an important impact 
on modern society because of its morbidity and 
mortality, associated complications requiring 
hospital care and often multiple reinterventions as 
documented in several epidemiological studies. In 
a previous study published recently in Portugal, a 
multidisciplinary group involving health scientists 
from the National School of Public Health and 
our group in the Academic Vascular Unit from the 
University Hospital Santa Maria in Lisbon aimed 
to quantify the impact of this disease in Portugal 
during the last eight years, expressed by the volume 
of admissions, treatment strategies and associated 
morbidity and mortality.
Data was collected from the Diagnosis Related Group 
national database on primary diagnosis, procedures 
codes, demographic variables, a number of risk 
factors, and mortality of all cases admitted from 2009 
to 2016 with a primary diagnosis of peripheral arterial 
disease coded according to the 9th revision of the 
International Statistical Classification of Diseases and 
Related Health Problems (ICD-9). 
In this study, peripheral arterial disease led to 27 
684 hospitalizations, which corresponded to 26.7% 
of all admissions for vascular disease in this period. 
Approximately 49.9% of patients were admitted 
to the emergency department. The volume of 
procedures in patients with claudication decreased 
over the eight years, unlike patients with critical 
ischemia, in which the number of procedures 
increased and a remarkable choice for endovascular 
techniques was noted. Age and the presence of 
cardiovascular risk factors have been associated with 
the severity of disease, as observed in our series. 
Overall hospital mortality varied, being significantly 
higher in patients with more advanced severity of the 
disease. There was a reduction on overall mortality in 
hospital admissions, but peripheral arterial disease 
continues to represent an important burden in the 
overall volume of admissions in Portuguese public 
hospitals with a large number of patients being 
admitted in the context of emergency. 
Subsequently we discuss in this presentation the 
impact of diabetes in Portugal concerning the 
number of minor and major amputations, review 
the available techniques to deal with CLTI with 
illustrative cases from our experience and analyze 
the new possibilities of endovascular treatment 
in comparison with open surgery and present our 
criteria for selection to the type of revascularization 
according to surgical risk, life expectancy, severity of 
disease and availability of suitable vein conduit.
We conclude for the need of a better stratification 
in the global assessment of the patient status, 
severity and extension of arterial disease in order 
to better stratify the clinical situation and obtain 
relevant prospective data on the preference for 
type of revascularization, open or endovascular and 
to analyze its cost-effectiveness as well long-term 
benefit for the patients.
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ANGIOGENESIS INDUCTION IN BUERGER’S DISEASE: A DISEASE 
MANAGEMENT DOUBLE-EDGED SWORD?
Bahare Fazeli, Shayan Keramat, Ladan Asadi
Mashhad University of Medical Sciences, Mashhad, Iran
bahar.fazeli@gmail.com
Keywords: Thromboangiitis Obliterans, Buerger’s 
disease, Angiogenesis, Endothelial cell, Treatment
Due to unknown aetiology of Thromboangiitis 
obliterans (TAO), its effectively treating is challenging. 
However, angiogenesis induction is one of the 
acceptable treatments for TAO patients. Recently, 
we have noticed that TAO patients who were under 
long-term treatment with angiogenesis-inducing 
medication showed considerable improvement in 
terms of healing chronic ulcers over the course of 
one to 2 years of treatment. However, some of them 
developed dermal gangrene despite the warming 
of their feet, with or without palpable pulses in the 
extremities, and with hair growth on the affected skin. 
Unfortunately, following the progression of dermal 
gangrene, some of these patients had to undergo 
amputation and limb loss. During histopathological 
evaluation, we detected some changes in the 
amputee TAO patients under long-term angiogenic 
medical treatment that were not present in 
amputee TAO patients who had not received any 
treatment for many years. The greatest pathological 
changes were observed in the microvascular of the 
skin, appearing as a proliferation of endothelial 
cells, NETosis and thrombus formation inside the 
vessels with proliferation of endothelial cells. The 
immunohistochemistry for CD31 and Ki67 as markers 
of vascular endothelium differentiation and cell 
mitosis confirmed the proliferation of endothelial 
cells. However, in the patients who had not received 
any treatment for years the typical pathology view of 
BD, including preserved vascular architecture with 
infiltration of inflammatory cells and inflammatory 
cells inside the thrombus, organised thrombus with 
recanalisation and intimal thickening was observed. 
Further longitudinal cohort studies regarding 
long-term treatment with angiogenic medications 
for TAO in different geographic areas are highly 
recommended.
PAD AND RADIATION PROTECTION
RADIAL ACCESSS FOR PERIPHERAL VASCULAR INTERVENTIONS AND 
DIAGNOSTICS
Tomislav Krčmar1, Nikola Kos2, Boris Car2, Mislav Vrsalović2
1Clinical Hospital Center Rijeka, Croatia
2Clinical Hospital Center “Sestre milosrdnice”, Zagreb, Croatia
tomsilav.krcmar@gmail.com
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Transradial approach is frequent procedure in 
treatment of percutaneous coronary interventions 
while the same approach is still used rarely in 
treatment of peripheral artery disease.The main 
advantages of the transradial approach concerning 
the potential complications (less minor and major 
bleedings assossiated with vascular in comparison 
to femoral) are very well known as well as the 
advantages in the means of comfort for the patient. 
In University Clinical Centre “Sestre milosrdnice” from 
2012 to 2017 transradial approach was used in total 
of 158 cases of invasive diagnostics or interventional 
treatment. In 48 situations it was used as one of the 
additional approaches within the main intervention 
on iliac arteries, whilst in 60 cases the transradial 
approach was the main route for the intervention 
on iliac arteries. TASC A lesions was treated in 64% 
of patients and 35% patients had TASC B lesions. 
In 50 cases radial approach was used for invasive 
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diagnostics. Except 5 minor hematomas there were 
now reported access site-related complications. All 
procedures were performed in cath lab with high 
radial volume in coronary interventions. Transradial 
approach in patients with peripheral artery disease is 
mainly reserved for the interventions on iliac arteries 
with rising numbers in interventions on femoral 
arteries. Transradial approach is safe and reliable 
method for interventions on peripheral arteries. 
More data and dedicated interventional devices 
are needed to establish radial access a standard 
procedure.
PAD AND RADIATION PROTECTION
RADIATION PROTECTION IN VASCULAR SURGERY
Jelena Popić 
Medical School Univesity of Zagreb, University Hospital Merkur, Zagreb, Croatia
popic.je@gmail.com
Keywords: radiation protection, endovascular 
procedures, dose , dose area product, radiation risk
There is growing concern regarding the radiation dose 
delivered during vascular interventional procedures, 
particularly in view of the increasing frequency and 
complexity of these techniques. Therefore, nowdays 
the importace of radiation protection in vascular 
interventions is growing.
These procedures have a potential for high 
exposures to both the patient and the medical stuff. 
The collective effective dose to the population due 
to interventional procedures is approximately 10% 
even though they account for only 1% of the number 
of procedures, making interventional procedures 
a significant contributor to the stochastic risk of 
patients.
Studies have, on the other hand showed, increased 
prevalence of left-sided brain tumors, cataract and 
thyroid disease for interventionalists.
Understanding how to avoid or minimize radiation 
effects is an important responsibility of everyone 
involved in the medical process. The key basic 
principles in understanding radiation protection 
are: justification, optimization and dose limits. Othe 
knowledge of otimisation of the medical procedure is 
crucial in terms of dose to the patient and personnel. 
The three main dose reduction techniques are: 
time, distance and shielding. In order to ensure this, 
adequate training of the medical staff is of great 
importance.
Understanding all parts of radiation protection will 
not only benefit the patient, but all the medical staff 
as well.
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PAD AND RADIATION PROTECTION
RADIATION EXPOSURE RISKS DURING ENDOVASCULAR PROCEDURES 
Nicos Angelides
University of Nicosia, Cardiovascular Unit of the Nicosia General Hospital, Nicosia, Cyprus
n_angelides@hotmail.com
Endovascular procedures represent an important part 
of a vascular surgeon’s practice. However, exposure of 
interventionists to ionizing radiation and safety issues 
have not been well studied in the past. As a matter of 
principle, the effective body, eye, thyroid and hand 
radiation doses of all participating surgeons and staff 
should be measured by mini-thermo-luminescent 
dosimeters (TLD) attached at the chest level under 
a lead apron, at the forehead about the eye level, 
inside and outside the thyroid protector and at the 
hand area. Also, the type of procedures, fluoroscopy 
machine and fluoroscopy time, as well as personal 
and operating theatre radiation protection devices 
have to be checked regularly. 
It has been demonstrated that during straight forward 
procedures the cumulative ionizing radiation dose is 
not exceeding usually the maximum safety levels. On 
the contrary, in complex cases i.e. (a) endovascular 
treatment of infrarenal aortic aneurysms, or (b) 
introduction of branched and fenestrated grafts for 
treating thoraco-abdominal aneurysms and aortic 
dissections, the radiation dose for vascular surgeons 
and interventionists is enormously increased. 
To-day, there is an obvious interest in the professional 
radiation risk. Although the trunk and the thyroid 
gland are well protected by lead garments, the eye 
lens and hands are at risk of high exposure. It has been 
shown that during simulation of an endovascular 
aortic procedure, with a 10 seconds period of 
fluoroscopy in DSA modus, the eye lens is receiving a 
median radiation dose of 0.02 μSv/s while the fingers 
of 0.41 μSv/s. According to the International Council 
for Radiation Protection, a threshold of 20 mSv/y was 
judged critical for operators’ lens exposure. 
Formal radiation safety training for vascular trainees 
is based on ALARA strategies {“As Low as Reasonably 
Achievable”}. An anonymous survey was distributed 
to our vascular trainees. It was found that 50% of the 
responders had no formal radiation safety training. 
From the remaining 50%, a significant percentage 
(64%), were unaware of ALARA radiation safety policy 
for pregnant females. Also another 40% did not know 
their radiation safety officer and a 33% were unaware 
of the yearly acceptable levels of radiation exposure. 
On the contrary, untrained residents knew more 
basic radiation safety regulations but relied mainly 
on other trained residents. Main ALARA strategies 
are: 
(a) Keep the patient away from the radiation source. 
(b) Keep the detector close to the patient. 
(c) Keep angulation to a minimum. 
(d) Step back during acquisition. 
(e) Use personal protective equipment. 
(f ) Use lead shielding on the fluoroscopy unit. 
(g) Limit fluoroscopy on time. 
(h) Lower the exposure rate wear lead gown and  
      protective eye wear. 
(i)  Use lowest-needed magnification. 
(j)  Limit fluoroscopy on time. 
In conclusion radiation protection is a serious 
issue for vascular surgeons because most complex 
endovascular procedures are delivering high 
radiation to various parts of the body and especially 
to the eyes. All operating endovascular surgeons and 
interventionists should undertake a mandatory basic 
and special course in radiation physics and radiation 
protection. Finally, the whole staff is encouraged to 
use all available protection measures such as lead 
screens, under table lead aprons and optimum 
source-to-object distance.
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VASCULAR AND ENDOVASCULAR SURGERY IN SLOVENIA
Vojko Flis
Department of vascular surgery, University medical center Maribor, Slovenia
vojko.flis@guest.arnes.si
Keywords: vascular surgery, endovascular surgery, 
specialty, education
In past decades there was no specialty in vascular 
surgery in Slovenia. This does not mean that there 
was no vascular surgery. However, young surgeons 
had to pass board exam in general surgery and after 
that they were prepared to gather experience in 
the field of vascular surgery. Meanwhile emerging 
interests of other competing specialties in Slovenia, 
especialy invasive radiology, had pushed into the 
field of vascular care. In Europe new specialization 
called vascular and endovascular surgery emerged. 
Continuous technological innovation drives the need 
for sub-specialisation to provide disease-centred 
expertise; however, treatment success equally 
depends on balanced patient-centred care. Vascular 
surgeons in Slovenia are amidst this controversy 
and are currently challenged by their own demand 
to offer all aspects of vascular care – as “the vascular 
specialist”. This presentation discusses the natural 
driving forces towards sub-specialisation and 
appraises advantages and limitations with respect to 
the future of integrated vascular care in Slovenia.
UEMS / YOUTH session IUA / ESVST
HOW TO BECOME A VASCULAR AND ENDOVASCULAR SURGEON AS WELL AS 
ENDOVASCULAR SPECIALIST IN GERMANY
Amir Arnautović, Hubert Schelzig
Clinic for vascular and Endovascular Surgery; University Clinic Duesseldorf, Germany
Amir.Arnautovic@med.uni-duesseldorf.de
Keywords: education, vascular endovascular 
surgery, Germany
Aim of the presentation is to present the structure 
of educational and training program of vascular and 
endovascular surgery in Federal Republic of Germany. 
Residency program for vascular surgery is determined 
by medical chamber from each constitute State of 
Germany and lasts at least 72 months. It contains 
basic surgical program during the first two years 
(24 months), as well as special educational program 
for vascular surgery in a period of 48 months. Basic 
surgical program includes at least 6 months at 
Emergency Department, 6 months at Intensive Care 
Unit, as well as 12 months of clinical practice in the 
theater, on the station and at the ambulance. Special 
educational program for a vascular surgeon has a 
focus on diagnostics as well as conservative and 
operative/endovascular treatment of the vascular 
diseases. During the program a resident needs to 
perform at least 250 diverse operations as well as 
certified radiation protection courses.
The educations and courses such as Doppler-
ultrasound course of different degrees and good 
research practice courses should be completed 
during the residency program. Although research 
work is not official part of the program, it is highly 
appreciated to get involved into clinical and basic 
science projects. This is especially the fact in university 
clinics as well as in university teaching hospitals.
Training program for endovascular surgeon and 
endovascular specialist has been organized by 
German vascular association. Training program 
for endovascular surgeons includes four different 
programs: basic program, abdominal aorta, pelvic 
arteries and legs arteries. Endovascular specialist 
program contains 7 different specials courses 
(carotid, thoracic aorta, pelvic and visceral arteries, 
legs arteries, treatment of deep veins, treatment of 
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special entities (v. cava superior and inferior, Trauma, 
pulmonary Embolism, A-V Malformation).
Educational and training programs for a vascular and 
endovascular surgeon, as well for an endovascular 
specialist are strictly defined and organized programs 
that are regularly adapted to new developments at 
vascular surgery.
UEMS / YOUTH session IUA / ESVST
VASCULAR SURGERY IN CROATIA
Marko Ajduk
University Hospital Dubrava, Zagreb, Croatia
majduk@yahoo.com
During the past two decades vascular surgery has 
been thoroughly changing What was expected 
from a vascular surgeon 20 years ago, is no longer 
sufficinet for someone to be addressed as a modern 
vascular surgeon. Development of endovascular 
techniques and benefit they added to treatment 
of the vascular patients forced vascular surgeons 
to adopt these techniques at least to some extent 
By adopting endovascular techniques, vascular 
surgeons provided that vascular surgery didn’t 
become obsolete and marginalized speciality.
Accordingly, the education of vascular surgery 
trainees needed to be changed to adapt to these new 
cicrumstances. Many european countries changed 
their vascular surgery training program to provide 
that new generations of vascular surgeons/specialits 
are able to treat vascular patents in best possible way, 
by either open or endovascular techniques.
This changes were adopted in Croatia about 7 years 
ago, and the first generation of vascular trainees 
trained according to the new program finished their 
training last year. Up to 10 new medical doctors 
start their vascular training in Croatia each year. This 
new program lasts for 63 months of which the first 
24 months is general surgery training. Throughout 
the training, each trainee is beeing supervised by 
his mentor who should take care that his trainee 
accomplish all goals of the training program. After 
they finish the training programm, trainees must pass 
the final exam which consists of oral and practical 
part. When they pass the exam they become vascular 
surgeons. They are also encouraged to take the UEMS 
exam, however the number of those who become 
FEBVS so far is only one.
The two main problems the new trainees face are 
the availability of the equipment for endovascular 
procedures needed for training and the insufficient 
number of vascular surgeons (mentors) provicient 
in endovascular tecniques who could educated 
them. As a result, they spend the most part of their 
endovascular education at radiology departmets and 
once they become vascular surgeons they don’t have 
adequate equipment within their vascular surgery 
departments (at the moment there is only one 
dedicated hybrid vascular operating room in Croatia).
Vascular surgery training is closely related to the 
development of vascular surgery, and main goals 
should be providing adequate education and 
equipment (more hybrid operating rooms) but based 
on thorough analyzis of needs of croatian population 
for vascular surgery service. One of cornerstones of 
that development is centralization of vascular service 
for most complex procedures. Only in those centers 
vascular surgeons can achieve sufficinet number of 
procedures they perform that can result in acceptable 
tretment results.
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IMPROVING TRAINING OPPORTUNITIES IN EUROPE: EUROPEAN VASCULAR 
SURGEONS IN TRAINING (EVST)
Stefano Ancetti 
Vascular Surgery Unit, University of Bologna, Italy
On September 5th 1994 the European Association of 
Vascular Surgeons in Training (EAVST) was established 
from an idea of Prof. Paaske. EAVST changed its name 
in European Vascular Surgeons in Training (EVST) 
and during the last 25 years represented European 
trainees in vascular surgery with the aim to promote 
knowledge and skills, improve networking, connect 
different Europeans countries enabling trainees to 
share experiences in different educational strategies 
and helping develop educational activities in 
collaboration with the European Society for Vascular 
Surgery (ESVS) and its Academy.
All the ESVS registered trainees under the age of 35 are 
automatically considered EVST members. In the last 4 
years we observed an exponential increase of EVST 
registrations. In 2019 EVST members represent more 
than Ľ of all ESVS registrations (743/2719=27,3%).
EVST is lead by the EVST Council, the decision-making 
body, that in 2019 is composed by 21 European 
countries. Every European country with at least 
10 EVST members can elect a representative in the 
Council that represents the link between that country 
and the ESVS. Some of the benefits ESVS gives to EVST 
members are represented by the chance to organize 
and chair scientific session, participate training 
session and symposia, be part of European Journal 
of Vascular and Endovascular Surgery (EJVES) review 
and guidelines writing committee. It finally provides 
Travel Grants and Congress Grants to visit foreign 
centers and congresses for free. EVST represent 
an outstanding chance for trainees to get the best 
training opportunities in Europe.
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EUROPEAN VASCULAR SURGEONS IN TRAINING (EVST). CALL FOR CROATIA.
Leonid Magnitskiy1, Stefano Ancetti2
1Pirogov City Hospital №1, Moscow, Russia
2Vascular Surgery Unit, University of Bologna, Italy
fosgin@mail.ru
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The European Vascular Surgeons in Training (EVST) 
is part of the European Society for Vascular Surgery 
(ESVS). The aim of the EVST is to provide an equal 
level of knowledge and skills for European trainees 
in vascular surgery and to improve interaction and 
networking within the trainees of European countries. 
What do members benefit from? Subscription to 
the European Journal of Vascular and Endovascular 
Surgery – the leading journal in vascular surgery 
(impact factor 3.642), free registration and grants for 
congresses such as Charing Cross, EVC, CACVS, MEET, 
LIVE; international fellowship opportunities, and much 
more. The EVST is led by the Council that is currently 
composed by more than twenty representatives 
from United Kingdom, Austria, Belgium, Denmark, 
France, Greece, Germany, Italy, Slovakia, Switzerland, 
Romania, Portugal, Spain, Netherlands, Sweden, 
Norway, Finland, Ireland, Bulgaria, Norway, Russia, 
Serbia, and Island. The Council meets three times a year 
to discuss current issues and to organize workshops 
and socializing events. These meetings are held at the 
European Vascular Course – EVC (March, Maastricht, 
the Netherlands), the Charing Cross Meeting (April, 
London, UK) and at the Annual Meeting of the ESVS 
(September, yearly changing locations). We enjoy 
working together, trying to do things better for the 
743 trainees currently registered with ESVS. Every 
European country with at least 10 members of the 
EVST may nominate a national representative to the 
Council. What are you waiting for? Join us!
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SYMPTOMATIC AAA AND CHRONIC STANFORD A DISSECTION
Kristina Tomašić
School of Medicine, University of Zagreb, Zagreb, Croatia
Aneurysm of the abdominal aorta (AAA) occurs 
7 times more often than TAA. In 96% of cases 
enlargement of the abdominal aorta is infrarenal 
and up to 70% of the AAA extends to one or both 
iliac arteries. Patients are mostly asymptomatic 
therefore the diagnosis is incidental. Risk factors that 
accelerate the onset of aneurysms include arterial 
hypertension, arteriosclerosis, smoking and genetics. 
Absolute indications for surgery are AAA diameters 
greater than 55 mm and growth dynamics greater 
than 5 mm in the last 6 months or more than 10 mm 
per year, as well as symptomatic aneurysms.
A 78-year-old man, due to a long-term finding of 
Stanford A dissection and a new-found symptomatic 
infrarenal abdominal aortic aneurysm, and 
associated left iliac artery aneurysm, was referred 
for detailed assessment and surgery done under 
general anesthesia during which a resection of the 
infrarenal abdominal aortic aneurysm and the left 
iliac aneurysm as well as reconstruction using a 
bifurcation transplant on the aortofemoral left and 
aortoiliac right side was performed.
Despite the extremely high perioperative risk, the 
complexity of the procedure, the patient’s age and 
comorbidity, and the possibility of a fatal outcome, 
surgery was still performed. We decided not to treat 
chronic, asymptomatic Stanford A aortic dissection 
Successful treatment of symptomatic AAA prevented 
possible rupture and death.
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MINOR AND MAJOR AMPUTATIONS
LIMB SALVAGE PROCEDURE VERSUS AMPUTATION – THE CREDIBILITY OF 
MANGLED EXTREMITY SEVERITY SCORE (MESS) IN SEVERELY INJURED LIMBS
Ali Allouch, Damir Koprek, Neven Mesar, Victor Allouch, Zrinka Sudar-Magaš, Branko Fila 
General Hospital Bjelovar, Bjelovar, Croatia
ali.allouch@obbj.hr
Keywords: mangled extremity, mangled extremity 
severity score, salvage versus amputation, lower 
extremity trauma
Background: Massive extremity trauma, in 
particular, complicated fractures associated with 
vascular injuries, present immediate and complex 
decision-making challenge between a limb salvage 
attempt and a primary amputation. While the 
evolution of sophisticated surgical reconstruction 
techniques has brought possibilities of successful 
limb salvage in even the most extreme cases, these 




A 74-year old lady was admitted in our emergency 
room due to her left leg injury after a truck ran over it. 
She was hypotensive (100/70mmHg), pale with a faint 
dorsalis pedis and posterior tibial artery pulse on the 
left leg. Two thirds of the left upper leg in its anterior 
aspect was struck by a skin defect and a muscle crash 
injury. Femoral medial condyle fracture, collateral 
genicular ligaments and joint capsule tear was found 
as well. According to the Gustillo classification, this 
injury was estimated as 3B and to MESS 8.
After haemodynamic stabilisation, a wound 
exploration revealed a posttraumatic spasm of the 
middle third of superficial femoral artery which 
recovered after 2% xylocaine application to its wall 
and 1mL to its lumen (Kimmonth’s technique).
Instable knee was treated by the external fixator type 
Zagreb 1. After the negative pressure wound therapy 
(NPWT) led to clean granulation tissue appearance 
in the wound, a split-thickness skin graft (Tiersch 
0,3) combined with NPWT 80mmHg was applied. 
Rehabilitation therapy led to complete recovering in 
the 6 weeks of the treatment. 
Patient 2
A 59-year old motorcyclist participated in a traffic 
accident. He was brought pale, hypotensive 
(90/70mmHg). Skin defect took two thirds of his right 
forearm. Volar and dorsal muscles were crushed. An 
X ray revealed multiple fractures of ulnar and radial 
diaphyses combined with radial head dislocation. 
The injury was estimated as Gustillo 3B and MESS 9.
Both radial and ulnar arteries were found in a spasm 
recovered after xylocaine application. Fracture was 
treated by the Hoffman external fixator. The skin 
defect was treated afterwards by a Tiersch graft 
0,3mm. 6 months later, the external fixation was 
replaced by AO spongioplasty due to non-union 
signs. On the third postoperative day a dynamic 
splint rehabilitation was indicated.
Conclusion: Complex limb salvage procedures must 
advocate safe and fast recovery with satisfactory 
function in cooperation of a multidisciplinary team.
Even though the MESS score greater than 7 indicates 
the amputation, limb salvage is possible even in 
higher MESS score.
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INFECTIONS IN VASCULAR SURGERY
IN SITU ABDOMINAL AORTIC RECONSTRUCTION WITH CRYOPRESERVED 
ALLOGRAFT IN SETTING OF GRAFT INFECTION
Evgeniya Bulda, A Koren, G Sivak
Rabin Medical Center, Campus Beilinson, Petah Tikva, Israel
znaharkabulda@gmail.com
Keywords: Aorta Graft Infection Cryopreserved 
Homograft
Aim of the study: Vascular reconstruction in patients 
with prosthetic graft infections is one of the greatest 
challenges in vascular surgery and is associated 
with significant morbidity and mortality. Secondary 
Aortoenteric Fistula is rare ( incidence rate 1.6-4%) 
but fatal complication ( mortality rate 24-45%) after 
reconstructive surgery. In this case we demonstrate a 
successful aortic reconstruction with cryopreserved 
allograft in the setting of graft infection and 
Aortoenteric Fistula.
Materials and methods: This case report presents 
on a 66-year old male with infected aortobifemoral 
dacron bypass and Aortoenteric Fistula, vascular 
reconstruction of infected aortic graft was done with 
in situ cryopreserved allograft.
Three individual cryopreserved homograft elements 
(iliac artery and two femoral veins) were sewn 
together to create a new aortobifemoral bypass. The 
allografts were chosen to best match the recipient 
patient’s anatomic measurements and create a 
tension-free anastomosis.
Results: Postoperative CT-scan one month after 
discharge showed excellent result of the aortic 
homograft implantation with no signs of reinfection, 
thrombosis or aneurismal dilatation. In 90-day follow 
up the patient was not diagnosed with recurrence 
of initial infection and did not require reoperation. 
These results demonstrate an encouraging outcome 
after cryopreserved allograft implantation in set of 
abdominal aorta graft infections.
Conclusion: Cryopreserved human allograft is 
a viable alternative to vascular reconstructions 
of infected aorta. We believe that cryopreserved 
allograft should be considered a first line treatment 
of aortic infections in future and serve as acceptable 
alternatives when autologous or extra-anatomic 
prosthetic reconstructions are not possible.
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OPEN AND ENDOVASCULAR TREATMENT OF ABDOMINAL AORTA
OPEN SURGERY REPAIR OF RUPTURED GIANT INTERNAL ILIAC ARTERY 
ANEURISM: A CASE REPORT
Muhamed Djedovic1, A Hadzimehmedagic1, H Vranic1, D Totic1, B Imsirovic2
1University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina
2General Hospital “Prim.dr. Abdulah Nakas” Sarajevo, Sarajevo, Bosnia and Herzegovina
djedovicm@hotmail.com
Keywords: open surgery, giant ruptured internal iliac 
artery aneurysm, abdominal structure compression
Internal iliac artery aneurysms are very rare vascular 
malformations. Ruptured aneurysms of the internal 
iliac artery (IIA) are rare and challenging to treat 
surgically. Due to their anatomic location they are 
difficult to operate on and perioperative morbidity is 
high.
An 62-year-old male patient of high surgical risk 
was presented with pain symptoms and a palpable 
pulsatile right lower abdominal mass. He was operated 
8 years ago for a large infrarenal aortic aneurysm. 
Computed tomography angiography (CTA) revealed 
a ruptured giant right internal iliac aneurysm ( 101 
mm), left internal iliac aneurysm (40 mm), bilateral 
common iliac aneurysm ( right 34 mm, left 32.8 mm), 
(he had right urethral obstruction with dilation of the 
canal system of the right kidney, increased values of 
urea, creatinine and inflammatory parameters). He 
was successfully treated by aneurysmectomy and 
aortoiliac bypass.
Patient recovered completely and was discharged 
13 days after the procedure in a relatively good 
condition.
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LOWER LEG COMPARTMENT SYNDROME IN A PATIENT USING DABIGATRAN
Inga Đaković Bacalja1, Damir Koprek1, Tomislav Krejčir1, Dejan Baljak1,  
Mirjana Gracin2, Tomislav Meštrović3
1General Hospital Bjelovar, Bjelovar, Croatia 
2Special Hospital for Pulmonary Diseases Rockfellerova, Zagreb, Croatia 
3University Hospital Centre Zagreb, Zagreb, Croatia
inga.dj@gmail.com
Keywords: compartment syndrome; dabigatran; 
fasciotomy; extremity trauma; idaricuzimab
Background: Acute compartment syndrome is a 
limb-threatening condition mostly associated with 
trauma. An annual estimate of incidence is 0.7-7.3 
per 100000.1,2 Roughly, 2.8% of patients who sustain 
extremity trauma will require a fasciotomy.3 
Case presentation: A 74-year-old patient was 
presented to our emergency room with the injuries 
sustained during a tractor roll-over accident. The 
patient was taking dabigatran. He had a medical 
history of atrial fibrillation and two ischaemic strokes. 
Last dose of dabigatran was taken 9 hours before the 
accident. Clinical examination revealed a painful, pale, 
oedemic lower leg with blisters and a haematoma 
medially and faint peripheral pulsations. There were 
no signs of fracture on X ray. Fasciotomy was indicated. 
A specific antidote (idaricuzimab) wasn’t available in 
the hospital. Thus, preoperatively, 1g of tranexamic 
acid (TA) and 2U of fresh frozen plasma (FFP) were 
administered. A fasciotomy was performed 3 hours 
after the injury by a dual incision. A large haematoma 
was removed from posterior compartment. Muscles 
were found vital. Postoperatively, 2U of FFP and 2U 
of red blood cells more were administered.4 Wound 
dressing was performed every 3 days with a silver 
impregnated non-adherent wound dressing. On the 
9th postoperative day, a necrectomy of a necrosis on 
the dorsal edge of the medial incision was performed. 
We started to close the lateral incision by graduate 
secondary suturing. The patient is scheduled for a 
split thickness skin graft placement on the medial 
incision site.
Conclusion: Clinical examination and an early 
fasciotomy remain the cornerstone in diagnosis and 
a successful treatment of the extremity compartment 
syndrome.
Anticoagulant therapy appears to increase the risk of 
occurrence and severity of compartment syndrome.
In the absence of specific antidote (idaricuzimab) and 
prothrombine complex concentrate, antifibrinolytic 
and FFP are a safe procedure correcting a coagulant 
status in a patient in need of fasciotomy.
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DOSE DEPENDENT DRUG-DRUG INTERACTIONS WITH DABIGATRAN
Juraj Jug1, Ingrid Prkačin2
1School of Medicine, Zagreb, Croatia
2Clinical Hospital Merkur, Zagreb, Croatia
juraj2304@gmail.com
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Dose-dependent toxicity (type A reactions) can be 
predicted by known pharmacology of the used drugs. 
We assume that polypharmacy (concomitant use of 3 
or more drugs per day) can dose-dependently change 
the pharmacokinetics of dabigatran (Pradaxa R).
In our study we enrolled 17 patients aged from 70 to 
85 years taking dabigatran divided into two groups 
dependently of the drug dose (A=dabigatran 110mg, 
B=dabigatran 150mg, taken two times per day) and 
the number of the drugs they used (1: less than 
three drugs, 2: three or more drugs). We checked 
hemoglobin levels, prothrombin time (pt), INR, APTT 
and the number of erythrocytes in blood samples 
and erythrocyturia in the urine.
In the group A2 all parameters were statistically 
lower compared to the group A1 (hemoglobin levels 
79.71 vs 125.00 g/L, p=0.008; pt 0.41 vs 0.57, p=0.02; 
erythrocyte number 3.07 vs. 4.96, p=0.006; APTT 22.5 
vs 43.75 s, p=0.08), except INR which was significantly 
higher (1.9 vs 1.3, p=0.05). There were also differences 
when group B2 was compared to B1 (hemoglobin 
levels 125.50 vs. 158.33 g/L, p=0.01; pt 0.38 vs. 0.60, 
p=0.01; erythrocyte number 4.1 vs. 5.17, p=0.02; 
APTT 30 vs. 38.5 s, p=0.18; INR 2.05 vs 1.36, p=0.04). 
Erythrocyturia was noticed in all group B patients 
while in the group A the incidence was only 33%.
Drug-drug interactions are dose-dependent and 
very common in patients with polypharmacy where 
dabigatran in higher doses showed the bigger 
incidence of erythrocyturia and pt/INR changes. 
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Introduction: Performing eversion endarterectomy 
some difficulties arise. Firstly, it requires a great deal 
of coherence between the work of the surgeon and 
the first assistant, as well as a great experience of the 
latter. Secondly, in some cases, there are difficulties 
in visualizing the distal margin of the intima: in the 
absence of a rigid skeleton, the soft unchanged 
artery walls after removal of the plaque subside, 
making it difficult to visualize possible fragments of 
the intima. Thirdly, the cost of the error is high: with 
a random de-version, repeated eversion turns out to 
be impossible. It should be noted that the use of an 
eversion technique becomes difficult to implement, 
and sometimes impossible, with extended stenosis, 
since a very high allocation of the ICA is required, 
which increases the invasiveness of the operation 
and the difficulty of access. With prolonged stenosis, 
the carotid endarterectomy remains the option 
of choice. The modification used eversion carotid 
endarterectomy combines the advantages of both 
methods, and also eliminates the limitations of 
the carotid endarterectomy and eversion carotid 
endarterectomy.
Methods: The study included 64 patients: 33 
underwent eversion carotid endarterectomy 
(I group), and 31 – modified eversion carotid 
endarterectomy (II group). In 100% of cases, the 
intervention was performed under endotracheal 
anesthesia. Brain perfusion and the need for an 
intraluminal shunt were assessed using cerebral 
oximetra and retrograde pressure in the internal 
carotid artery. Exclusion criteria from the study: 
patients with a mouth injury of the ICA (plaque < 2 
cm), patients with a contralateral occlusion of the 
ICA, patients with stroke in ischemic type in the acute 
period.
Results: In our study, there were no cases of using a 
glove shunt. There were no hospital lethality, strokes, 
cases of transient ischemic attack and injuries of the 
cranial nerves in both groups. In group I, the clamping 
time of the internal carotid artery was 19.21 ± 1.47 
minutes, versus 14.94 ± 1.39 minutes, p < 0.05 in 
group II, respectively. The patient´s stay in the ICU in 
both groups did not exceed 1 day. In all patients, the 
wound healed by first intention. The average hospital 
stay did not exceed 6 days in both groups.
Conclusion: The use of a modified eversion 
carotid endarterectomy technique can reduce the 
clamping time of the internal carotid artery and, as 
a consequence, reduce the time of cerebral ischemia 
in patients with common lesions of the common 
carotid artery bifurcation.
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FOR VA SCUL AR REPAIR
Now Cleared for  
All Vascular Repair Procedures *
The only biologically complete,  
non-crosslinked matrix for vascular repair
*FDA 510(k) 140789, July, 2014
>> Kirit Patel M.D., Odessa, Texas
“Everything else is just a patch.”
The Evidence Is Clear in Peripheral Bypass
